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This thesis describes the synthesis of several small molecules, structurally related to 
SID3712502, which have shown promise as inhibitors of castration-resistant prostate cancer by 
preventing nuclear translocation of the androgen receptor.  This thesis also describes the 
preparation of a small library of α- and β-glycoslyated analogs of N-acetylglucosamine and N-
acetylgalactosamine, which were prepared from an oxazoline intermediate or by an acid 
catalyzed isomerization with the desired glycosyl acceptors.   The configuration of the lead 
compound, C34, was confirmed by synthesis and NMR studies.  Four glucosamine analogs and 
two galactosamine analogs showed promising in vitro anti-inflammatory effects.  These analogs 
were shown to be probes for reducing cytokine over-expression through inhibition of TLR4 and 
able to reduce the gross disease of necrotizing enterocolitis. 
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1.0  SMALL MOLECULES CAN TARGET THE ANDROGEN RECEPTOR 
NUCLEAR TRANSLOCATION IN CASTRATION-RESISTANT PROSTATE CANCER 
1.1 INTRODUCTION 
1.1.1 The Androgen Receptor and Prostate Cancer 
The androgen receptor (AR) is a 110-kDa ligand-inducible nuclear receptor of the steroid 
receptor family of transcription factors that regulates male developmental and physiological 
characteristics.1  Like other steroid receptors the AR has four functional domains which were 
determined by X-ray crystallography: the NH2-terminal domain with transcriptional activation 
function AF-1 (60% of the entire protein), a central DNA binding domain, a short hinge region, 
and a COOH-ligand/AF-2 cofactor binding domain.1b  When androgens testosterone and 
dihydrotestosterone (Figure 1) are bound to the AR, they mediate male sexual differentiation and 
pubertal sexual maturation, the maintenance of spermogenesis, and male gonadoptropin 
regulation.1a,1b  The complex can then either induce or repress expression of target genes.2  
Mutations of the AR can result in decreased androgen binding affinity, change its transcriptional 
activity, which leads to infertility, androgen insensitivity or prostate tumors.1a  
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Figure 1. Androgens 
 
Transcriptional activity of androgen-bound AR is altered by coregulatory proteins acting 
as coactivators or corepressors to hundreds of target genes, thus allowing for multiple 
mechanisms of transcriptional control (Figure 2).1a,3  Unbound AR is found in the cytoplasm 
complexed with several heat shock protein chaperones and high molecular weight 
immunophilins, which help induce a high-affinity ligand binding conformation.1b,1c  Androgen 
binding to the AR induces a conformational change and triggers dissociation from the 
cytoplasmic chaperone protein HSP90, self-dimerization and translocation into the nucleus 
where it binds specific genome sequences to activate target gene transcription (Figure 2).1c,3-4  
Dihydrotestosterone, synthesized by 5α-reductase enzymes from testosterone, is the main AR 
ligand in prostate tissue1a,1b and is bound 10-fold more tightly than testosterone.4  The prostate is 
an androgen-dependent tissue in which androgens trigger development and also regulate cellular 
growth/function.1b  It is this sensitivity to androgen levels and AR signaling that is important in 
controlling prostate cell homeostasis.5  Any change in AR expression levels, androgens, or 
alterations in the AR mode of action effect the physiology of the prostate.5   
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Figure 2. Regulation of the AR (reproduced with permission from Ref. 1c, Copyright Massachusetts Medical 
Society) 
 
Androgens and the AR are essential in the occurrence and progression of two disease 
states that occur in elderly males: prostatic hyperplasia and prostate cancer.1a,1b  The healthy 
human prostate is a tubular-alveolar gland with epithelial acini made up of basal and luminal 
cells that form a two-layered epithelium encapsulated in the stromal compartment.6  The AR is 
contained within the cytoplasm of stromal and secretory epithelial cells and prostate cancer 
occurs when the cellular homeostasis is altered.6  Prostatic hyperplasia, which can occur as men 
age, is an increase in epithelial cells that retain normal cellular function/size and are 
pathologically benign.6  Prostate cancer among US males is the most commonly diagnosed 
cancer besides non-melanoma skin cancer and is the second leading cause of cancer deaths.7  
Around $11.9 billion is spent in the United States every year on prostate cancer treatment.7  In 
2012 alone, the NCI estimated that 241,740 men would be diagnosed with prostate cancer and 
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28,170 would die from it.8  Prostate cancer incidence has a hereditary component but the major 
risk factor is increasing age5 and the number of prostate cancer cases is expected to increase as 
the average age of the population rises.6 
Cancer often occurs when the balance between proliferation and cell survival versus cell 
death is disrupted.  As the AR is responsible for controlling proliferation, differentiation, 
apoptosis and secretion in the prostate, the connection between AR signaling and cancer has 
made it a target for prostate cancer treatment.5-6  The first case of prostate cancer was described 
in 18539 and the discovery of the androgen dependency of the disease by Huggins and Hodges in 
the 1940’s made androgen deprivation therapy the accepted treatment.3  The cancer originates in 
the epithelial compartment of the prostate where overexpression of the AR and a change in 
function from pro-differentiation to pro-proliferation are required.5   
The changes in AR function happen through one or more of the following mechanisms: 
receptor mutations, alternative splicing of AR mRNA, changes in the levels of coactivators and 
corepressors, and activation of different cell signaling pathways.3,5  Somatic mutations are 
present in most prostate cancers and alter ligand affinity, coregulator interaction, dimerization, 
and stability of the AR.5  Coregulators of the AR can either increase or decrease AR activity and 
their overexpression leads to increased proliferation and reduced apoptosis.5  Inflammatory 
cytokines present in the body like IL-6, TNF-α, and IL-1β increase with age and IL-6, a target of 
NF-κB, has been linked to influencing AR function and thus prostate cancer.5  Higher levels of 
NF-κB are common in prostate cancer and they help maintain nuclear AR, interfering with the 
cell cycle, which increases proliferation and decreases apoptosis.5  The relationship between the 
AR, androgens, and prostate cancer progressions is more complicated than just depriving the 
cancer cells of androgen. 
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At diagnosis, 80-90% of prostate cancers are dependent on androgen-AR signaling as an 
activator of proliferation, as was first shown by Huggins and Hodges.10  Androgen deprivation 
therapy was initially accomplished surgically by removal of the testes or by chemical castration 
with estrogen until the successful synthesis of synthetic gonadotropin-releasing hormone 
(GnRH) polypeptide.9  Chemical castration with synthetic GNRH functions through a negative 
hormone feedback on the hypothalamus which in turn decreases levels of circulating 
testosterone.4,9  Surgical removal of the testes has been shown to lower circulating testosterone 
levels to <20 ng/dL while chemical castration with synthetic GNRH generated levels <50 
ng/dL.4  Despite these castrate levels of androgens, almost all patients relapse in 18-24 months 
leading to the development of castration-resistant prostate cancer (CRPC)9-10 which is currently 
incurable and responsible for all prostate cancer deaths.11   
Prostate specific antigen (PSA) and prostate acid phosphate (PAP) are two accepted 
biomarkers of prostate cancer which become upregulated when the disease evolves to castration-
resistant.3  These biomakers are often used in the clinic to identify when the disease has relapsed 
and are a good indication of CRPC.3,12  Amplification and overexpression of the AR is one of the 
most common changes in CRPC and the AR is able to localize to the nucleus independent of 
androgen levels.3  The AR also is postulated to have different roles in the stroma versus the 
epithelium and the basal epithelial cells versus luminal epithelial cells, acting as a tumor 
suppressor in one and a tumor proliferator in the other.10,13  This dual role of the AR in prostate 
tissues could help explain why androgen derivation therapy fails even in low-risk, early 
diagnosis patients.12    
CRPC was initially thought to be androgen-independent after initial castration treatment; 
however recent studies show AR remains dependent on androgens.3,11  The source of testosterone 
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and DHT at functional levels remains unknown and AR remains active in signaling pathways 
with lowered levels of androgens.11  The higher than expected tissue levels of testosterone and 
DHT observed in CRPC patients are enough to activate the AR and it is proposed that intracrine 
metabolism of adrenal androgens or plasma membrane cholesterol may be responsible.14  Upon 
castration in a mice model, AR exited the nucleus but re-entered and rebound the PSA enhancer, 
showing in vivo activation of the AR even at castrate levels of androgen.15  AR overexpression16 
and knockdown17 studies show that the AR is a key molecular determinant and is critical for 
proliferation and progression of the CRPC cancer.  Increased AR cellular concentration is 
required for the progression of CRPC, can change antagonists into agonists, and can alter the 
coactivators interaction with the receptor.16  Current prostate cancer therapy is focused on 
inhibiting androgen activation of the COOH-terminal domain of the androgen receptor through 
androgen deprivation therapy, antiandrogens, or disruption of steroid metabolic pathways.4,18     
Antiandrogens are small molecules that compete with androgen for the binding of the 
AR.18  Antiandrogens, while increasing patient survival initially, have not been able to prevent 
the recurrence and evolution of the cancer to the castration-resistant state.18  It is hypothesized 
that the reason for this is the 50-500 fold higher AR binding affinity for the androgens over 
antiandrogens.18  Cyproterone acetate (Figure 3) was the first antiandrogen used for prostate 
cancer treatment in the 1966, and it has a long half-life and good bioavailability in vivo.9  The 
steroid core of the molecule allows it to function as an inhibitor of androgen-AR interaction and 
of gonadotropin secretion—an antiandrogen and a chemical castration agent in one.9  In the 
1970’s, this was a good alterative to chemical castration by estrogen as cyproterone acetate had 
better efficacy and fewer side effects.9 
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Figure 3. Traditional antiandrogens and Taxol-based inhibitors 
 
Flutamide is an antiandrogen, acetanilide-derived compound that acts as a prodrug.19  The 
active form is oxidized in vivo at the dimethylacetanilide functionality to 2-hydroxyflutamide 
(Figure 3), and it has been used in combination with GnRH agonists since 1989.9,19  A short half-
life in vivo requires dosing as high as 250 mg three times daily; however, the combo therapy is 
not effective in treating CRPC.19  A structurally related nitrotriflurotoluene based antiandrogen, 
nilutamide (Figure 3), has a longer half-life than flutamide but has more side effects than the 
other FDA-approved non-steroidal antiandrogens.20  It also does not increase patient survival in 
advanced prostate cancers.20   
Bicalutamide, a non-steroidal trifluoromethylbenzonitrile antiandrogen, is used in 
conjunction with GnRH therapy and is considered the current standard-of-care for prostate 
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cancer (Figure 3).21  Marketed as a racemic drug, the (R)-enantiomer has been found to be the 
principle active component, with the (S)-enantiomer being absorbed and cleared more rapidly.21-
22  The 60-fold difference in the effective in vivo dose of (R)- versus (S)-bicalutamide has been 
correlated to differing rates in drug metabolism.22  The (R)-enantiomer has also been shown to 
have a better binding affinity for the AR.21  Doses of 50 mg/day-150 mg/day are approved by the 
FDA for treatment of prostate cancer.9  Higher doses have shown promise as a monotherapy, 
improving patient survival in locally advanced prostate cancer.9 
BMS-641988 (Figure 3), is an oxabicyclo-imide-based antiandrogen that showed promise 
in Phase I clinical trials as a treatment for CRPC.9  When compared to bicalutamide, a 20-fold 
higher binding affinity for the AR, a 3-7 fold higher antagonistic potency, and an improved anti-
tumor activity in prostate tumor xenografts was observed.23  Because of these initial positive 
results, a Phase I dose escalation clinical study was initiated with 61 CRPC patients.  However, 
limited anti-tumor activity and an epileptic seizure in one patient resulted in termination of the 
trial.9 
Taxol-based chemotherapeutic agents (Figure 3) have shown promise in improving the 
quality of life over the short term for CRPC patients.24  Docetacel is currently seen as the 
standard-of-care in CRPC and has a survival benefit of 2-3 months.25  Taxol derivatives reduce 
expression of PSA gene through inhibition of the AR by an unknown mechanism.24  The current 
hypothesis is that taxol-based compounds increase the concentration of an AR suppressive 
nuclear factor, FOX01.24a  Docetaxel, while FDA approved for treatment of CRPC, suffers from 
many of the common taxol toxicities issues.25  Cabazitaxel is currently in Phase I clinical trials 
and may offer a better toxicity profile while prolonging survival in CRPC patients.  
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Figure 4. Modulators of AR activity 
 
Besides the traditional antiandrogens and taxol-based compounds, researchers have tested 
other approaches to disrupt the androgen-AR interaction.  MDV3100 and its structurally related 
analog RD162 (Figure 4) are diarylthiohydantoins based on the structure of nilutamide and are 
much more potent antiandrogens.26  MDV3100 was chosen as the clinical candidate for the 
treatment of CRPC after an extensive SAR study because of its strong receptor antagonism and 
good pharmacokinetic properties.26a  Unlike other antiandrogens, MDV3100 and RD162 were 
shown to be effective in the treatment of CRPC in a mouse model and in Phase I/II clinical 
trials.9,26b  MDV3100 and RD162 display a 5-8 fold higher binding affinity than the traditional 
antiandrogens, reduce the efficiency of receptor nuclear translocation, and impair binding to 
DNA and the recruitment of coactivators.26  However, MDV3100 can only increase survival by 
3-5 months in patients with CRPC.   
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Abiraterone (Figure 4) or abiraterone acetate binds irreversibly and highly selectively to 
the CYP17 enzyme, blocking the in situ production of androgens and reducing their 
concentrations to 1 ng/dL level.4  In CRPC patients, levels of PSA dropped >50% in 55% of the 
patients, and this treatment can be used to lower residual cellular androgen after androgen 
deprivation therapy.4  The compound is currently in Phase III clinical trials which are expected to 
be completed in 2014.  Sipuleucel-T (not shown), a cancer vaccine, was recently approved in 
2010 for the treatment of CRPC and might provide a 4 month survival advantage based on a 
recent study.27  Each vaccine is made specifically for the patient using autologous blood 
peripheral mononuclear cells, recombinant PAP–GM-CSF, T cells, B cells, natural killer cells 
and other cells from the hosts body.27  The vaccine is designed to harness the cell-killing of the 
immune response and may one day be used as a conjunctive therapy.  
Sintokamide A,28 crytoanshinone,29 and a DNA binding polyamide30 (Figure 4) inhibit 
AR activity through three unique mechanisms.  Sintokamide A was isolated from the marine 
sponge Dysidea sp. collected in Indonesia and was found to be the first inhibitor of the NH2-
terminus of the AR.28  As all current therapies focus on the COOH-terminus of the AR, this 
compound provides a novel lead for androgen receptor modulation.  Crytotanshinone is a known 
natural product/Chinese herbal medicine and it inhibits AR in normal prostate cancer cells and 
CRPC cells.29  Cryptotanshinone repressed AR signaling by blocking complex formation with 
lysine-specific demethylase 1 function and blocks AR dimerization.29  The structural similarity 
to DHT suggests that cryptotanshinone may act through a more common antiandrogen 
mechanism.  A DNA minor groove binding polyamide was found to inhibit the AR-DNA 
interaction and PSA levels were reduced in vitro at similar levels to bicalutamide.30  This 
polyamide represents another new approach to inhibit AR activity besides the traditional 
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androgen deprivation/antiandrogen treatments.  However, an inhibitor of AR nuclear 
translocation, which is essential for cell proliferation, is currently not represented in the 
literature.  Therefore, we chose to examine this as a possible treatment of CRPC. 
1.1.2 SID3712502 and Initial Hit Development 
N
O
S
N
O
N
SID3712502
 
Figure 5. The Hit (SID3712502) 
 
To examine our goal of identifying small molecules that block AR nuclear localization, 
we needed an assay that could test this hypothesis.  Our collaborators in Professor Zhou Wang’s 
lab at the University of Pittsburgh Medical Center were able to generate and stably transfect 
castration-resistant C4-2 cells with Green Fluorescence Protein (GFP) giving GFP-AR cells.  
These could then be used to study intracellular movement of the AR in vitro.  The C4-2 cells 
were also transfected with PSA6.1-Luciferase (PSA6.1-Luc) and Renilla-Cytomegalovirus (pRL-
CMV).  As PSA is a known biomarker of prostate cancer and related to the progression of the 
disease, monitoring of its release is related to translocation of the AR into the nucleus.3  The 
pRL-CMV releases PSA through a non-AR dependent pathway so this was monitored to 
demonstrate that the decrease in PSA was related to an AR dependent pathway.  A high 
throughput screen of ~260,000 small molecules from the UPDDI library identified an initial 
group of compounds, which were active at a single dose of 10 μM.31  These compounds were 
then dosed from 1 nM-50 μM, with the HSP-90 inhibitor 17AAG as a positive control and 
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DMSO as a negative control, and 35 compounds were selected based on their dose dependent 
response.31  Further analysis narrowed this list to 3 novel lead structures, all of which inhibited 
GFP-AR nuclear localization but not GFP-GR or GFP-ER in the C4-2 cell model.  SID3712502 
(Figure 5) inhibited proliferation of AR-positive cancer cell lines LNCaP, C4-2, LAPC4, 22Rv1 
and CWR-R1 at <1 μM and localized endogenous AR in C4-2 cells to the cytoplasm.31  C4-2 
xenograft tumor growth was inhibited in the mice model and no cell death at 10 mM was 
observed in any of the cell lines.31  The body weight of mice was also not affected, suggesting 
this class of molecules is not cytotoxic.    
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To probe the SAR of SID3712502, an initial 15 compounds were synthesized by Dr. Erin 
Skoda in the Wipf group.  Simple T3P coupling of several commercially available carboxylic 
acids and N-aryl piperazines gave 3 key structural variations: change in the substitution of the 
right aromatic ring, sulfur-carbon exchange in the 3 carbon linker, and variation of the isoxazole 
ring (Figure 6 and Figure 7).  The effect of phenyl dimethyl substitution on biological activity 
was studied by changing the methyl substituent at the ring, adding a methoxy group, and 
completely omitting substitution.  The o-methoxy was not tolerated in any of the analogs and the 
o-methyl was found to be essential to activity. This suggests that the orientation of the phenyl-
piperazine is critical to activity but that the hydrogen bond acceptor was disfavored.  The sulfur-
carbon exchange in the 3 carbon linker was tolerated, and the phenyl substitution for the 
isoxazole did not affect activity.  The importance of the piperazine core in SID3712502 was not 
investigated.      
N
O
S
N
O
N
Not 
explored
phenyl ring 
substitution
for isoxazole
tolerated
CH2 substitution 
tolerated
o-Me group essential
o-OMe not tolerated
 
Figure 7. First round of SAR results for SID3712502 
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1.2 RESULTS AND DISCUSSION 
1.2.1 Chemical Synthesis of SID3712502 Analogues 
Following the first round of SAR, a retrosynthetic analysis led to two pathways to alter 
each of the four designated zones in SID3712502 (Scheme 1).  Using Buchwald-Hartwig 
coupling conditions, we could probe the importance of the piperazine ring in zone 2 and the 
various substitutions and functionalities of the aromatic ring in zone 1.  This would then be 
followed by coupling with the commercially available isoxazolethioacetic acid (1-1) to rapidly 
access a diverse set of analogs.  The importance of the sulfur in the 3 carbon linker and the amide  
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Scheme 1. Retrosynthetic analysis 
 
 15 
functionality in zone 3 could be investigated by nucleophilic displacement of 1-3 and 1-4 with a 
variety of nucleophiles; this could be used to further probe the importance of the zone 4 
isoxazole by replacement with a variety of other aromatic heterocycles. 
Buchwald-Hartwig coupling with a variety of protected and unprotected heterocyclic 
diamines is precedented in the literature,32 and we employed this reaction to rapidly access 
variations of both zone 1 and 2.  The coupling of 3 different aryl halides with protected and 
unprotected diamines proceeded in moderate yields by heating in toluene in the presence of 
Pd2(dba)3 and racemic BINAP.  This allowed access to a pyridine derivative 1-5, a brominated 
tolyl derivative 1-6, and three different alterations in the piperazine core 1-7 to 1-9 (Table 1).  
The low yield for 1-9 is hypothesized to be from its ability to favorably act as a bidentate ligand 
to Pd, thus limiting its reactivity. 
Table 1. Buchwald-Hartwig coupling of diamines with aryl halides 
N
H
N 17%
73%
54%
32%
48%
Structure
X       Y       Z        R1        n
Pd2(dba)3 (1.0 mol % Pd), 
(rac)-BINAP (1.5 mol %), NaOtBu
toluene, reflux, 24 h
Y
X
Entry
1a
2b
3b
4
5
a The reaction mixture was stirred for 40 h, b The reaction mixture was heated at 80 °C
N
Z
O
O
Y
R1
N
Z
O
O
n
R1
Compound
1-5
1-6
1-7
1-8
1-9
Br      N      NH       H         1
Yield
I      CH     NH       Br        1
Br     CH     NH       H        2
Br     CH  CHNH2    H        1
n
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Boc-deprotection by HCl in dioxane of the diamines 1-5 to 1-8 proceeded in near 
quantitative conversion to the corresponding HCl salts.  T3P coupling with 1-1 gave the final 
compounds in good yield (Table 2, Entries 1-4).  Two commercially available amines (Table 2, 
Entries 5 & 7) and 1-9 were also coupled to 1-1 in good yields.  Replacement of the carbon 
opposite the essential o-methyl substitution with a nitrogen in 1-13 allowed examination of 
substituent effect beyond the initial methyl substitution variations.  1-10 similarly looked at this 
effect while adding a bromotolyl derivative that could be tritiated for analysis of where these 
compounds are actively binding the AR to prevent nuclear translocation.  1-11, 1-12, and 1-13 
examined the effect of changing the piperazine ring to a diazapine, piperidine, and freely rotating  
 
Table 2. Synthesis of zone 1 and 2 probes 
1-1, T3P, NEt3
CH2Cl2, rt, 20 h
quant.
quant.
93%
76%
4 N HCl
dioxane
N
N
O
S
O
N 76%
98%
quant.
N
O
S
O
Entry
1
2
3
4
5a
6a
7a
a Synthesis started from free amine
1-7
1-8
1-5
N
Z
O
O
Y
R1
R2
N
Z
Y
R1
R2
1-6
ClH2N
Z
Y
R1
R2
CompoundBoc-Protected Amine
Structure
Y       Z        R1     R2        n
N       N        CH3   H         1
CH     N       CH3    Br        1
CH     N       CH3    H         2
CH  CHNH   CH3   H         1
CH     N           F      H        1
Yield
1-10
1-11
1-12
1-13
1-14
1-15
1-16
CCl     N        CH3   H        1
n n n
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ethylenediamine linker.  1-14 and 1-16 examined the effect of chlorine substitution opposite the 
o-methyl and direct replacement of the o-methyl with fluorine, respectively. 
For developing the SAR of zones 3 and 4, we chose to synthesize the precursors 1-3 and 
1-4 by condensation of chloroacetyl chloride and chloromethanesulfonyl chloride, respectively, 
with o-tolylpiperazine, which resulted in high yields under basic conditions (Scheme 2).  The 
alcohol nucleophiles 1-18 to 1-19 and 1-2 were prepared in good yields from the corresponding 
aldehydes and carboxylic acid by reduction with NaBH4 and LiAlH4, respectively (Scheme 3).  
The formation of methyl ester 1-17 under methanolic HCl conditions proceeded in moderate 
yield (Scheme 3).  Combination of 1-3 and 1-4 with alcohols 1-17 to 1-19 and 1-2 would allow 
access to probes of zone 3 amide substitution, sulfur to oxygen replacement in zone 3, and 
variation of the aromatic heterocycle in zone 4. 
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Scheme 2. Synthesis of alkylating agents 
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MeOH
78%
NaBH4
THF
92%
NaBH4
THF
quant.
LiAlH4
THF
80%
1-17
1-18
1-19
1-2  
Scheme 3. Synthesis of heterocyclic alcohols (zone 4) 
 
1-20 to 1-23 were accessed using literature conditions for the condensation of allyl 
alcohols with chloroacetamide.33  The heterocyclic alcohols 1-17 to 1-19 and 1-2 were premixed 
with sodium hydride at 0 ºC followed by addition of 1-3 and warming to room temperature 
(Table 3).  After stirring overnight, 4 variations of zone 3 and 4 were obtained where 1-17 allows 
attachment to a resin for surface plasmon resonance (SPR) protein affinity analysis, 1-18 and 1-
19 probe the importance of the 5-methyl group in the thiophene for biological stability, and 1-2 
examines the effect of oxygen substitution for sulfur.  The two different thiophenes 1-18 and 1-
19 were also added to probe the zone 4 heterocycle effect.  All of these compounds were 
submitted to the Wang lab for in vitro testing in C4-2 cells. 
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Table 3. Synthesis of zone 3 and 4 probes 
S
N
N
O
O
S
S
N
N
O
O
S
1-22
1-23
O
O
N
N
O
O
O
O
1-20
N
O N
O
O
N
O
N1-21
N
N
O
Cl
NaH
THF, 0 °C-rt, overnight
N
N
O
OAr
OHAr
Entry Alcohol Product
1
2
3
4
1-17
1-2
1-18
1-19
1-3
Yield
34%
90%
70%
35%
 
 
Besides the analogs described above, which were submitted for testing in December 
2012, we were more recently able to synthesize 1-24 (Scheme 4).  Our original synthetic plan 
was to prepare an analog of SID3712502 by direct substitution of the amide functionality of zone 
3 with a sulfonamide through nucleophilic displacement of the chloride of 1-4 as had been done 
previously with the analogous 1-3. All attempted conditions however failed and only recovered 
starting material 1-4 was isolated in each case.  1-24 will be submitted in due course to probe not 
only the amide replacement with the sulfonamide but also the shortened zone 3 linker. 
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Scheme 4. Synthesis of sulfonamide analog 1-24 
1.2.2 Biological Evaluation 
The Wang lab at the University of Pittsburgh Medical Center tested the synthetic analogs 
in their in vitro assay to see if they blocked AR nuclear localization similar to SID3712502.  All 
compounds were first tested at 10 μM and 5 more active derivatives were then tested by dose 
dependent response, 0 μM to 12.8 μM.31  The C4-2 cells were not transfected with GFP-AR as 
was done previously but instead used the endogenous AR found within the cells.  This makes it 
difficult to directly compare this data directly to the first round of SAR.  The previously 
unexplored piperazine ring in zone 2 was investigated by adding a carbon to the piperazine ring 
to give a diazepine derivative (Table 4, Entry 1), moving the one of the nitrogens outside the 
piperazine ring (Table 4, Entry 2), eliminating the ring for a more freely rotating 2 carbon linker 
(Table 4, Entry 3), and adding cis-dimethyl substitution to the piperazine core (Table 4, Entry 4).  
The cis-dimethyl derivative was found to be toxic to the cells at 10 μM, while the loss of the 
more restricted ring structure also decreases activity.  The diazepine derivative and moving the 
nitrogen outside the piperazine ring however was effective in reducing the IC50 to ~1.0 μM for 
both compounds (Table 4, Entries 1 and 2).    
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Table 4. AR inhibition by zone 2 probes31 
N
N
N
N
N
N
H
N
N
N
O
S
R
O
1
2
3
4a
Entry R
Cells detached, toxicity
~0.8 µM
---
~1.0 µM
Estimated IC50b % Reduction
c
91%
91%
66%
aCompound was synthesized by Mustafa Kazancioglu. bC4-2 (endogenous 
  AR) cells transfected with PSA6.1-Luc and pRL-CMV and treated with 0.05,
  0.2, 0.8, 3.2, 12.8 µM doses of compound for 24 h; lysed cells analyzed by 
  Firefly and Renilla luciferase with a Dual-Luciferase Reporter on a LmaxII384 
  luminometer; Firefly luciferase values (AR dependent PSA release) were 
  normalized to Renilla (AR independent PSA release); Estimated IC50 values 
  represent the point when the normalized Firefly luciferase values were reduced 
  by half relative to DMSO (0 µM) control; performed in triplicate. cTreated with 
  a 10 µM dose of compound for 24 h and results analyzed same as above; 
  performed once; Percent reduction values represent decrease of the normalized 
  Firefly luciferase values relative to DMSO (0 µM) control.  
 
 The synthetic probes of zones 1, 3, and 4 revealed less about the SAR for these analogues 
of SID3712502 than originally hoped (Table 5).  None of the isoxazole zone 4 replacements 
were tolerated (Table 5, Entries 10-15) and with the exception of the sulfonamide derivative 
(Table 5, Entry 9).  However, direct ether linker replacement for the thioether of SID3712502 
was not tolerated (Table 5, Entry 4) suggesting that the poor activity of the heterocycle 
replacement may be from the zone 3 N-methyl or ether linker and not the zone 4 component.  O-
methyl replacement in zone 1 with a cyano group (Table 5, Entry 1) was tolerated and well as a 
naphthyl group in place of the o-tolyl zone 1 functionality (Table 5, Entry 2) from SID3712502.  
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Halogen substitution around the zone 1 aromatic ring (Table 5, Entry 6) was also tolerated as 
long as the essential o-methyl group was retained.  Initial second round SAR results show 
promising trends (Figure 8) however, more complete dose dependent analysis of all the 
submitted analogs is need to confirm the trends and accurately calculate IC50 values.  It appears 
Table 5. AR inhibition by zone 1, 3, 4 probes31 
S
O
O
O
OO
O
O
N
O
N
O
O
O
S
O
O
S
O
O
O
O
N
O
X
N
O
N
R1
CN
N
Cl
F
X = S
X = S
X = S
X = O
X = S
X = S
X = S
X = S
Entry
1a
2a
3a
4
5
6
7
8
N
N
R2
9a
10a
11a
12a
13
14
15
Entry R2R1X
Br
~0.6 µM
~1.5 µM
---
---
---
---
---
--- 44%e
---
---
~0.4 µM 76%e
39%e---
---
---
--- 64%e
Estimated IC50b % Reduction
c Estimated IC50b % Reduction
c
aCompounds were synthesized by Mustafa Kazancioglu. bC4-2 (endogenous AR) cells transfected with PSA6.1-Luc and pRL-CMV and 
  treated with 0.05, 0.2, 0.8, 3.2, 12.8 µM doses of compound for 24 h; lysed cells analyzed by Firefly and Renilla luciferase with a 
  Dual-Luciferase Reporter on a LmaxII384 luminometer; Firefly luciferase values (AR dependent PSA release) were normalized to Renilla 
  (AR independent PSA release); Estimated IC50 values represent the point when the normalized Firefly luciferase values were reduced 
  by half relative to DMSO (0 µM) control; performed in triplicate. cTreated with a 10 µM dose of compound for 24 h and results analyzed 
  same as above; performed once; Percent reduction values represent decrease of the normalized Firefly luciferase values relative to 
  DMSO (0 µM) control. dIncrease in PSA release observed versus DMSO control. eNon-AR dependent PSA decrease.
78%
89%
7%
36%
70%
44%
48%
28%
0%d
11%
38%
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that no other zone 4 rings other than the isoxazole from the hit or phenyl ring from the first round 
of SAR are tolerated.  The zone 3 sulfur linker cannot be substituted for the more metabolically 
stable ether or N-methyl linkers.  Two different rings other than the zone 2 piperazine were 
tolerated and various substitutions around the zone 1 aromatic ring were tolerated as long as 
ortho-substitution was maintained.  More importantly, the second round of SAR revealed several 
analogues with 4 exceptions (Table 5, Entries 5-8) that were active and selective for the AR 
dependent pathway of PSA release; this selectivity was not observed in the hit or in any of the 
compounds for the first round of SAR.     
N
O
S
N
O
N
Other heterocycles
not tolerated
Ether, N-methyl linker
not tolerated
-Diazapine tolerated
-Exo-nitrogen piperidine tolerated
-Piperazine ring substitution and
 ethylenediamine not tolerated
-o-cyano, fluoro tolerated
-napthyl tolerated
-pyridine with o-methyl tolerated
-various halogen substitution tolerated
  with o-methyl
 
Figure 8. Second round of SAR results for SID3712502 
1.3 CONCLUSIONS 
The new synthetic analogues of SID3712502 have allowed us to expand our original 
hypothesis and to increase selectivity and potency.  The second round of SAR has allowed 
further confirmation that zone 1 ortho-substitution is essential and repositioning of this 
functionality with different zone 2 ring systems, diazepine or by moving the nitrogen outside the 
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piperazine ring, allows a better binding fit.  This exact binding interaction could be confirmed by 
a tritium labeling experiment or by synthesis of the zone 4 methyl ester derivative for a SPR 
experiment (Figure 9), as the originally synthesized ether analogue was not active (Table 5, 
Entry 15).  The sulfur in the zone 3 linker could not be replaced by oxygen or methylated 
nitrogen as had been done in the round 1 SAR with carbon.  More stable analogous forms of 
oxidized sulfur (Figure 9) could be synthesized to further probe what is important to activity in  
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Figure 9. Planned analogs and ongoing work 
 
zone 3.  As it is currently not known if any other heterocycle besides the phenyl or isoxazole ring 
is tolerated in zone 4, the synthesis of a sulfur linked imidazole could probe this hypothesis.  
Tying back the ring with the benzofuran in zones 3 and 4 could determine if restriction across 
zone 3 while maintaining a zone 4 aromatic substituent could improve biological activity.  Cis-
dimethyl substitution on the opposite side of the piperazine ring (Figure 9) could test if two 
different analogs can act as o-methyl mimetics and determine if this piperazine substitution is 
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also toxic in the cell lines as was observed previously.  The most important next step is the full 
biological characterization of the first two rounds of SAR to obtain IC50 values that can be 
directly compared.     
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2.0  SYNTHESIS OF N-ACETYLGLUCOSAMINE DERIVATIVES FOR 
MODULATING TLR4 IN NECROTIZING ENTEROCOLITIS 
2.1 INTRODUCTION 
2.1.1 Toll-like Receptor-4 and Necrotizing Enterocolitis 
 The human immune system protects itself from pathogens by avoidance, resistance and 
tolerance.34  Avoidance reduces risk of exposure, resistance fights off the infection once 
established, and tolerance limits the negative impact of the immune upregulation on the host 
without decreasing the resistance.34  The immune system can be subdivided into the innate 
immune system and the adaptive immune system.  Adaptive immunity accounts for the 
generation of T-cells and B-cells with immunological memory to elicit a more effective and 
more rapid immune response in the case of re-infection by the same pathogen.34-35  Innate 
immunity however acts as the body’s first responder and determines the nature and level of the 
immune response based on the molecular signatures present.35-36  Toll-like receptors (TLR) are 
members of a family of pattern-recognition receptors that are essential in the ability of the innate 
immune system to recognize pathogens and pathogen-associated molecular patterns (PAMPs) 
(Figure 10).35-37  In mammals, 13 TLR are known (11 in humans) and they are responsible for 
differentiating self from non-self, which includes bacteria, fungi, viruses, and protozoans.37a,37c  
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TLR are type I transmembrane receptors responsible for detecting conserved metabolic products 
unique to microorganisms but absent from the host.35-36   
 
Figure 10. TLR and their ligands (reproduced with permission from Ref. 35) 
 
Molecular signatures of microbial metabolism, such as bacterial lipopolysaccharide 
(LPS), lipoprotein, peptidoglycan, and lipoteichoic acid (Figure 11), are conserved but not 
exactly the same across a species of pathogens.35,37b  The lipid-A portion of LPS (Figure 11) is an 
invariable pattern across all Gram-negative bacteria and thus triggers a response of the innate 
immune system while the rest of LPS is not conserved and elicits no response.35-36,37b   Each of 
the 11 mammalian TLR, which can be aided by other proteins, recognizes specific PAMPs and 
more than one TLR can recognize certain ones.35-36,37b  TLR4 was the first characterized 
mammalian Toll and it is expressed mostly in immune cells like macrophages and dendrites.35,37b 
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Figure 11. Lipid A portion of LPS and lipoteichoic acid 
 
TLR4 recognizes LPS from Gram-negative bacteria, lipoteichoic acid from Gram-
positive bacteria and RSV F protein.35-36,37b  A complex between an extracellular protein MD-2 
and TLR4 is required for receptor recognition of LPS, although its exact function is unknown.35-
36  Upon binding, LPS is delivered to the cytoplasm of the cell where further signaling is 
induced.35-36,37b  TLR4 has the ability to recognize heat-shock proteins, specifically HSP60, 
produced by necrotic tissue and compounds like Taxol interact with the TLR4-MD2 complex in 
mice but not in humans.35-36  Activation of TLR4 and other TLR leads to stimulation of 
intracellular transduction pathways and stimulates genes which trigger the release of 
inflammatory cytokines, chemokines, major histocompatibility complex (MHC), and co-
stimulatory molecules.35-36  Once the receptor is activated by an extracellular ligand, NFκB and 
mitogen activated protein (MAP) kinases induce transcription of immune response genes.35  This 
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triggers the release of cytokines like IL-1β, TNF-α, IL-6, and IL-2 for immunological defense of 
the host.35  The release of cytokines can have a negative effect on the host which leads tissue 
damage or other physiological costs caused by the infection or the immunological response to 
that pathogen.34-35  TLRs have been recently linked to influencing the induction of cell 
autophagy as a mechanism of defense by the innate immune system to fight off infection.37a 
Beyond the desired scope of the innate immune response, TLRs have been linked to 
human inflammatory and immune diseases.  The broad expression of TLRs throughout the body 
and their ability to recognize a diverse set of PAMPs poises them to act as both a key to host 
immune defense and susceptible to react to local tissue damage.38  TLR are implicated in severe 
sepsis and systematic human inflammatory response syndrome (SIRS),39 Crohn’s disease,40 acute 
pancreatitis,41 arthritis,42 and atherosclerosis.43  More recently, a connection has been proposed 
between LPS, TLR4, and necrotizing enterocolitis.44 
Necrotizing enterocolitis (NEC) is one of the most prevalent and devastating diseases in 
premature infants occurring in 7% of all infants with a birth weight of 500-1500 g and a 
mortality rate of 20-30%.45  The first cases were reported in the 1960’s and the disease has 
proved very difficult to eradicate.45  Premature birth results in high morbidity and mortality due 
to infections caused by immaturity of the innate immune system and the invasive medical 
operations these infants often undergo.46  The more sensitive innate immune response of 
premature infants can result in an excessive inflammatory response causing necrotizing 
entercolitis, which affects the tissue of the small intestine and can even prevent neurological 
development.45  The hypothesized cause(s) of the diseases are as follows: a genetic 
predisposition, intestinal mucosa immaturity, abnormal microbial colonization of the intestine 
compared to non-premature infants and a highly reactive innate immune system (Figure 12).44-45  
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Research in the last 5-10 years has pointed to TLR signaling playing a major role in the 
progression of NEC in neonatal infants.44  In NEC murine models, a connection between the 
overexpression of TLR4 in enterocytes and intraluminal bacteria has been observed47 and 
reciprocal signaling between TLR4 and TLR9 is important in the development of NEC.48  TLR4 
is known to disrupt the balance between intestinal mucosa injury and repair further establishing a 
connection between NEC and TLR4.49  
 
Figure 12. Necrotizing enterocolitis (reproduced with permission from Ref. 45, Copyright Massachusetts Medical 
Society) 
 
Because toll-like receptors (TLRs) have been linked to massive upregulation of the 
immuno-inflammatory response and cancer they have become major targets for drug discovery.50  
To date there are 3 TLR4 antagonists in the developmental phase as targeted therapeutics: 
Eritoran (Figure 13) from Eisai pharmaceuticals (suspended in Phase III), AV411 from Avigen 
(Phase II), and NI0101 from NovImmune (Preclinical).50  The crystal structure of the TLR4-MD-
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2 complex with the Eritoran antagonist bound was recently reported in the literature, giving more 
information about the TLR4-MD-2 active site interaction.51  Eritoran is a second generation 
synthetic structural analogue of Lipid A and has been evaluated thoroughly in the literature.51-52  
Synthetic TLR4 antagonists include mainly Lipid A mimetics, and are structurally similar to 
Eritoran in size and lipophilicity.  Structural modifications that have been studied include 
changing both the nature of the lipid side chains or eliminating one of the pyranose rings of the 
core.53  One of these Lipid A mimetics, CRX-526, had anti-inflammatory effects in two murine 
models for inflammatory bowl diseases like Crohn’s disease and ulcerative colitis.  There has 
been some evidence that some opioids may have TLR4-MD-2 modulation properties while have 
having no opioid receptor activity.54  A 17 residue peptide mimetic of MD2-I was found to block 
association of the full length MD-2 with TLR4 which is needed for LPS mediated activation.55  
To date, there is no known treatment for NEC, but considerable research in the last 10 years has 
focused on its associated receptor, TLR4. 
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Figure 13. Structure of TLR4 modulator, eritoran 
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Carbohydrates are involved in a multitude of biological processes and are often called 
nature’s third biopolymer.56  Monosaccharides in nature can form oligo- and polysaccharides or 
can exist as glycone structures attached to peptides, lipids, or natural products.56a,57  2-Amino-2-
deoxyglycosides, which mainly contain glycosides of N-acetylglucosamine, make up an 
important portions of glycoconjugates found in human milk, human blood, in bacterial 
lipopolysaccharide antigens and in plant root cells.58  Human milk oligosaccharides are thought 
to have anti-inflammatory properties59 which would explain why there is a lower incidence of 
inflammatory disease, like NEC, in breast-fed (BF) versus formula-fed infants.60  Artificial 
oligosaccharides added to formula are structurally different than those naturally occurring in 
human breast milk.60-61  While specific oligosaccharides are involved in the effect, the exact 
structure-function relationship is not clearly understood.59a,61   
Glucosamine (Figure 14) is a known treatment for pain maintenance of osteoarthritis and 
has no adverse side effects when compared to NSAIDs nor does it affect glucose metabolism.62  
It has also been shown to have anti-inflammatory abilities to reduce the expression of cytokines 
by inhibiting NFκB activity in human retinal pigment epithelial cells63 and in mouse arthritis 
models.64  N-Acetylglucosamine has even been proposed as a replacement for glucose as an 
osmotic solute in peritoneal dialysis fluid due to its lack of pro-inflammatory effects and good 
toxicity profile.65  Post-translational modification of nuclear and cytoplasmic proteins by O-
glycosidic attachment of β-N-acetylglucosamine was shown to be necessary for cell viability and 
under cellular distress helped improve the tolerance of cells to a variety of stimuli.66  
Glucosamine and N-acetylglucosamine derived glycoconjugates have shown promise as central 
scaffolds for the development of glycosylated drugs. 
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Figure 14. Nitrogen-containing monosaccharides common in nature 
2.1.2 The Hit: C34 
Lipid A mimetics structurally similar to Eritoran have become popular synthetic targets 
in the recent literature due to their biological activity.53a,53b,67  An in silico similarity search based 
on the structure of Eritoran tetrasodium (E5564) was performed by Dr. Peter Wipf to identify 
lead compounds using the iResearch System Library of ChemNavigator®, the substance 
similarity Tanimoto scores implemented in SciFinder®’s substructure module, and 
ChemAxon®’s JChem® tools.  An initial 700 hits were narrowed to approximately 10% and 68 
individual compounds were chosen based on their commercial availability and chemical 
diversity.  The 68 compounds were tested in mice for their ability to inhibit TLR4 signaling after 
LPS injection and in vitro for their ability to inhibit LPS induced TLR4 cytokine upregulation in 
both hematopoietic and epithelial cells.   Compound C34 (Figure 15) was selected as the rapid 
synthesis of diverse analogs from common intermediates was straightforward and due to its 
potency and selectivity in the initial screen.  However, the supplier, Enamine, could not provide 
the configuration of the 5 stereocenters in the C34 pyran ring, complicating the resynthesis.  Our 
initial hypothesis was that C34 was either a derivative of glucosamine or galactosamine with α- 
or β-configuration at the anomeric carbon.  Therefore, we initiated the synthesis of these 
compounds (Figure 15) as well as several other analogs for SAR purposes. 
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Figure 15. C34 and 4 possible stereoisomers 
2.2 RESULTS AND DISCUSSION 
2.2.1 Analogue Chemical Synthesis and the Configuration of C34 
As the glucosamine core of C34 makes up the central disaccharide scaffold of both Lipid 
A (Figure 11) and Eritoran (Figure 13), we sought to mimic their lipophilicity while reducing the 
molecular weight of our SAR analogs to make them more drug-like in character.    Our strategy 
examined 3 areas of diversity: α- vs β-glycosidic linkage, C-4 configuration of the pyranose ring 
(glucosamine vs galactosamine), and varying the length, size, and lipophilicity of the glycosyl 
chain.  The pyranose hydroxyl and amino groups were acetylated to mimic the longer chains in 
Lipid A and Eritoran. 
Glycosylation methods for 2-amino-2-deoxyglycopyranosides are derived from the 
traditional literature protocols for carbohydrates but are distinctly different due to the C-2 
nitrogen.58a  Glycosylation of 2-acetamido-2-deoxy-D-glucosamine (N-acetylglucosamine, 
GlcNAc) under standard Koenigs-Knorr conditions, while proceeding with good stereoselectivity 
for the 1,2-trans-glycoside, resulted in a large amount of the oxazoline side product.58a   The 
conditions were further limited to reactive glycosyl acceptors with a primary hydroxyl group.58a  
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The N-acetyl group forms an oxazolinium intermediate which upon loss of a proton gives the 
oxazoline.58a,68  Because of the tendency of GlcNAc glycosyl donors to form the oxazoline, 
various alternatives to the N-acetyl group have been examined in glycosylation reactions69 
including protection with phthaloyl,70 tetrachlorophthaloyl,71 4,5-dichlorophthaloyl,72 
dithiasuccinoyl,73 trichloro-74 and trifluoroacetyl,74a,75 trichloroethoxycarbonyl,76 diacetyl,77 
dimethylmaleoyl,78 thiodiglycol79 groups or masking as the 2-azido group.58b,80  While these 
groups provide an alterative to the oxazoline issue, each requires additional steps for the 
protection and subsequent substitution with the N-acetyl group of the desired compounds.  Ring 
opening of aziridines such as those generated from iodosulfonamidation of glycals81 or from the 
photolysis triazolines82 present two other approaches for the formation of 2-amino-2-
deoxyglycopyranosides.  However, a more recent publication by Wittmann and co-worker 
showed promise for an opening of these oxazolines with a variety of glycosyl acceptors under 
mild copper (II) catalyzed conditions.68 
We decided that opening of the oxazoline with a variety of alcohol nucleophiles would 
allow rapid access to the β-glycosylation analogs of 3,4,6-tri-acetyl-N-acetylglucosamine and 
3,4,6-tri-acetyl-N-acetylgalactosamine all from the same key intermediate 2-1 (Scheme 5).  The 
α-glycosides were imagined to be synthesized from an acid catalyzed isomerization of the 
corresponding β-glycosides.   
O
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Scheme 5. Retrosynthetic analysis for β-anomers of 2-acetamido-2-deoxy-D-pyranosides 
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After synthesis of the fully protected β-pentaacetates of galactosamine 2-583 and 
glucosamine 2-1184 using literature conditions, the corresponding oxazolines 2-6 and 2-12 were 
synthesized in high yields using the Jeanloz’ protocol with TMSOTf in 1,2-dichloroethane.85  
Other literature methods to access the glyco-oxazolines using SnCl4 in dichloromethane failed.86  
2-6 and 2-12 were then heated at reflux in CHCl3 with CuCl2 and the desired glycosyl acceptors, 
giving the β-glycosides in good yields (Scheme 6) under the mild reactions conditions developed 
by Wittmann.68  Using isopropanol, cyclohexanol, and geraniol as the glycosyl acceptors, we 
were able to synthesize 6 derivatives, with 3 pairs of different configurations at C-4.  Glycosidic 
linkage with isopropanol gave compounds 2-7 and 2-13 with a small alkyl side chain whereas the 
cyclohexyl linked derivatives 2-8 and 2-14 where slightly larger in size.  The geraniol glycosidic 
linked compounds 2-9 and 2-15 gave two more lipophilic derivatives, mimicking the longer acyl 
side chains of both Lipid A and Eritoran. 
O
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Scheme 6. Synthesis of 6 β-glycosides of 2-acetoamido-2-deoxy-D-glucose and galactose 
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The α-glycosides proved more difficult to access than we originally thought, and all acid 
catalyzed isomerization conditions with the corresponding β-glycosides were unsuccessful.  
Fortunately, literature conditions for the synthesis of the methyl α-D-glucosamine from D-
glucosamine pentaacetate were found to give the desired products.87   Heating the fully protected 
β-glucosamine and β-galactosamine pentaacetates (2-11 and 2-5 respectively) in 5% HCl in 
alcohol solvent cleanly gave a 3:1 mixture of the α:β isomers, which after reprotection with 
acetic anhydride in pyridine were separated by chromatography on SiO2 to give the α-glycosides 
2-16 to 2-18 in moderate yields (Table 6).  Compounds 2-16 and 2-17 allowed examination of 
the effect of the C-4 configuration on the α-glycosidic linkage with isopropanol (Table 6, Entries 
1 and 2) as well as comparison to the corresponding β-glycosides 2-7 and 2-13.  The synthesis of 
α-glycoside 2-18 placed the cyclohexyl group opposite that of 2-14 allowing for comparison of 
the activity of α- and β-glycosidic linkage as well as the size of the α-glycosidic substitution 
compared to 2-16 and 2-17. 
Table 6. Acid mediated synthesis of the α-glycosides 
O
AcO OAc
NHAc
OAc
O
AcO
AcHN
OAc
OR
AcCl, ROH, 65 °C, 1 h;
Ac2O, pyr, rt, 2 d
Entry R Yield
1
2
3
i-Pr
i-Pr
Cyclohexyl
61%
57%
57%
Configuration
α
β
α
AcO AcO
Product
2-16
2-17
2-18  
 
As the configuration of C34 was unknown, we initially imagined that the commercial 
compound was a mixture of multiple compounds.  However, we were delighted to discover by 
1H-NMR and 13C-NMR that C34 was a single compound.  We compared the NMR of the 
commercial sample to those of the four proposed stereoisomers we had synthesized, glucosamine 
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derivatives (2-16 & 2-13) and galactosamine derivatives (2-17 & 2-7).  1H-NMR and 13C-NMR 
spectra of the four possible stereoisomers when compared to the spectral data for C34 revealed 
that 2-13 closely resembled C34 but that of 2-16 matched exactly when the spectral data was 
overlaid (Figure 16 and Figure 17).  To further support our claim, a co-NMR of C34 (2 mg) and 
2-16 (2 mg) was also measured and the spectrum was identical to the previous NMRs (Figure 16 
and Figure 17).   
 
Figure 16. 1H-NMR of C34, 2-16, and a 1:1 mixture of both compounds 
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Figure 17. 13C-NMR of C34, 2-16, and a 1:1 mixture of both compounds 
 
The coupling constants for H1-H2 (J = 3.7-3.8 Hz), correspond to α-configuration at the 
anomeric carbon, and the chemical shift of the anomeric carbon further supported our hypothesis 
that C34 was indeed equal to 2-16 (Table 7).  The chemical shifts of all the protons and carbons 
within the three sets of data as well as the coupling constants for each proton were the same 
within the error of the instrumentation.  With this data we felt confident in confirming that C34 
was identical to 2-16 and had the structure and configuration as pictured below in Table 7.   
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Table 7. NMR studies of C34 vs 2-16 
O
AcO
AcHN
AcO
OAc
O
2-16
400 MHz
2-16 + C34a
600 MHz
H1 H2 H3 H4 H5 H6 H6'NH
C1 C2 C3 C4 C5 C6 CH(CH3)2 CH(CH3)2C(O)CH3C(O)CH3
C34
400 MHz
2-16
100 MHz
2-16 + C34a
150 MHz
C34
150 MHz
a) 1H-NMR comparison of C34 vs 2-16 in CDCl3
b) 13C-NMR comparison of C34 vs 2-16 in CDCl3
Compound
Compound
a2-16 + C34 were mixed in a 1:1 ratio in an NMR tube
a2-16 + C34 were mixed in a 1:1 ratio in an NMR tube
5.62, d 
 J = 9.6 Hz
4.93, d 
 J = 3.8 Hz
4.35-4.27, m 5.20, app. t 
 J = 10.4 Hz
5.11, app. t 
 J = 10.0 Hz
4.05-3.99, m 4.23, dd 
 J = 4.8, 12.2 Hz
4.09, dd 
 J = 2.4, 12.4 Hz
171.4, 170.7,
169.8, 169.3
95.7 71.471.068.2 67.7 62.151.9 23.2, 23.1,
21.6, 20.8
20.7, 20.6
171.4, 170.7,
169.8, 169.3
95.7 71.471.068.2 67.7 62.051.8 23.2, 23.1,
21.6, 20.7
20.7, 20.6
171.4, 170.7,
169.8, 169.3
95.7 71.471.068.3 67.7 62.151.9 23.2, 23.1,
21.6, 20.8
20.7, 20.6
5.62, d 
 J = 9.6 Hz
4.92, d 
 J = 3.8 Hz
4.34-4.26, m 5.19, app. t 
 J = 10.4 Hz
5.10, app. t 
 J = 10.0 Hz
4.05-3.98, m 4.22, dd 
 J = 4.8, 12.4 Hz
4.08, dd 
 J = 2.4, 12.4 Hz
5.61, d 
 J = 9.6 Hz
4.93, d 
 J = 3.7 Hz
4.33-4.28, m 5.20, app. t 
 J = 10.2 Hz
5.10, app. t 
 J = 10.2 Hz
4.05-3.98, m 4.22, dd 
 J = 4.8, 12.6 Hz
4.09, dd 
 J = 2.4, 12.6 Hz
2-16
400 MHz
2-16 + C34a
600 MHz
C34
400 MHz
CH(CH3)2 CH(CH3)2C(O)CH3
3.89, sept 
 J = 6.4 Hz
2.09, 2.03, 
2.02, 1.95, 4 × s
1.25, d; 1.15, d 
 J = 6.4 Hz;  J = 6.0 Hz
3.88, sept 
 J = 6.4 Hz
2.08, 2.02, 
2.01, 1.94, 4 × s
1.24, d; 1.14, d 
 J = 6.4 Hz;  J = 6.0 Hz
3.89, sept 
 J = 6.0 Hz
2.08, 2.03, 
2.02, 1.94, 4 × s
1.24, d; 1.15, d 
 J = 6.0 Hz;  J = 6.0 Hz
 
 
With the configuration of C34 confirmed by resynthesis and several analogs completed, 
we also prepared a tritium labeled version of 2-14 to probe the binding mode of action for these 
compounds.  We wanted to know if C34 and its analogues inhibited TLR4 via direct binding or 
through another mechanism, such as allosteric interaction.  Wild type and TLR4 knockout RAW 
macrophages could then be treated with this tritium labeled derivative and the labeled compound 
was detected in a scintillation counter.  Hydrogenation of 2-19, which was prepared by treatment 
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of 2-12 with cyclohexenol under Wittmann’s conditions, with 10% Pd/C under an atmosphere of 
H2 proceeded smoothly to give a near quantitative yield of the saturated cyclohexyl glycosylation 
product (Scheme 7).88  With successful conditions for hydrogenation of 2-19, we switched the 
gaseous atmosphere to tritium generated by a Trisorber system were able to access the tritium 
labeled compound 2-20 with a 57.6 Ci/mmol specific activity.   
 
 
O
AcO O
NHAc
AcO
EtOAc, rt
97%
O
AcO O
NHAc
AcO
OAc OAc
T2, Pd/C
EtOAc, rt
O
AcO O
NHAc
AcO
OAc
T
T
H
H2-19 2-14
H2, Pd/C
2-20a
aCompound was synthesized by Dr. Peter Wipf  
Scheme 7. Synthesis of the tritium-labeled analog 
2.2.2 Biological Results 
The Hackam group at Children’s Hospital in Pittsburgh tested the synthetic analogs in 
vitro and in vivo against experimental NEC models.  In the glucose series, 2-13, 2-14, 2-16 and 
2-18 were shown in macrophages to reduce the levels of inflammatory cytokines triggered by 
LPS by 30-50% (Table 8).  Only 2-8 and 2-9 in the galactose series showed a similar consistent 
activity across the cytokines examined (Table 8).  This suggests that while the smaller isopropyl 
and cyclohexyl glycosyl groups were tolerated, the geraniol based analogs were too bulky to 
bind the receptor.  There is also little difference between the active α- and β-analogs in both 
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series.  While 2-7 was not able to reduce cytokine expression in vitro, overall there seemed to be 
little difference between the glucose and galactose series.  This suggests that the configuration at 
C-4 of the O-acetyl group in the pyranose ring is not important for activity and that this group 
could possibly be eliminated in future analogs. 
 
Table 8. In vitro percent reduction of cytokines in mouse RAW macrophages induced by LPS 
O
AcO O
NHAc
OAcAcO
O
AcO O
NHAc
AcO
OAc
Pyranosides
2-7
2-8
2-9
2-13
2-14
2-15
2-16
2-18
2-17
TNF-α IL-6 iNOS
Percent Reduction in Cytokinesa
24 ± 8% 32 ± 16% ---
38 ± 3% 48 ± 6% 65 ± 12%
7 ± 6% 24 ± 15% ---
3 ± 2% 2 ± 19% ---
30 ± 9% 36 ± 9% ---
18 ± 7% 50 ± 8% ---
42 ± 5% 55 ± 6% 62 ± 8%
48 ± 8% 39 ± 2% 53 ± 10%
46 ± 4% 33 ± 6% 51 ± 9%
aRAW 264.7 macrophages were treated with 10 µM of compound 
  to 10 ng/mL of LPS and analyzed by qRT-PCR; N > 4 for each 
  group; the percent reduction in cytokines is calculated by
  comparison to 10 ng/mL of LPS alone; Saline and the compounds
  alone showed no effect.  
 
In vivo testing in an inflammatory mouse model with 2-14 and 2-16 showed that these 
two analogs significantly reduced the NFκB upregulation caused by LPS injection versus the 
control.  Furthermore, 2-16 was shown to preserve the intestinal mucosa, reduce the gross 
disease and inflammatory cytokine expression, and lower the NEC severity score in both a 
mouse NEC model and in ex vivo isolated small intestine from infants with NEC.  The tritium 
analog of 2-14 (Scheme 7) was shown by Professor Jeff Brodsky and co-workers at the 
University of Pittsburgh Department of Biology to directly bind to TLR4.  In an in vitro labeling 
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assay with wild type and TLR4 knockout bone-marrow derived macrophages, the tritium labeled 
2-20 bound wild type TLR4 expressing macrophages ~1.5 times more favorably than the TLR4 
knockout macrophages.  This data partially supports the initial hypothesis that the mechanism of 
action for all of these analogs might involve a direct binding interaction with TLR4.  The in vitro 
reduction of cytokines, the in vivo reduction in the severity of NEC, and the direct binding 
supported by the interaction of 2-20 preferentially with wild type macrophages suggests that 
these analogs of C34 represent novel probes for modulating overactivation of TLR4 and diseases 
states like NEC.     
2.3 CONCLUSIONS 
β-Glycoslyated analogs of N-acetylglucosamine and N-acetylgalactosamine were rapidly 
access from their precursor oxazolines 2-12 and 2-6, respectively, while the α-glycosides were 
synthesized through an acid catalyzed isomerization in 5% alcoholic HCl with the desired 
glycosyl acceptor.  Glucose analogs 2-13, 2-14, 2-16 and 2-18 and galactose analogs 2-8 and 2-9 
showed good reduction of cytokines in vitro and in vivo.  2-14 and 2-16 were shown to attenuate 
the severity of NEC in a mouse model by reducing cytokine expression.  The originally unknown 
configuration of the commercial lead compound C34 was assigned by synthesis and NMR 
studies to be identical to 2-16.  The synthesis of the tritium-labeled analog 2-20 showed that this 
series of compounds may interact directly with TLR4, confirming our initial design strategy 
based on Eritoran.  2-16 was shown to preserve the intestinal mucosa, lower the levels of 
inflammatory cytokine expression and reduce the gross disease of NEC in both mouse intestines 
and ex vivo isolated human intestinal tissue.  This series of analogs represents probes for 
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reducing inflammatory cytokine over-expression by inhibition of TLR4 and reducing the gross 
diseases of NEC.  As it is currently unclear from the SAR presented herein if the β- or α- 
configuration at the anomeric carbon is preferred or if the O-acetyl function at C-4 is necessary, 
future synthetic analogues and biological studies should focus on the synthesis of more 
metabolically stable and possibly further simplified pyranosides.  
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Figure 18. Proposed future synthetic analogs of C34 
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3.0  EXPERIMENTAL SECTION 
3.1 GENERAL 
All moisture sensitive reactions were performed using syringe-septum techniques under 
an atmosphere of either dry N2 or dry argon unless otherwise noted. All glassware used in 
moisture sensitive reactions was flame-dried or oven dried at 136 ºC overnight and cooled in a 
desiccator prior to use. All chemicals were purchased from commercial suppliers and unless 
otherwise noted were used as received. Tetrahydrofuran was dried by distillation over 
sodium/benzophenone under an argon atmosphere. Dry methylene chloride, dry dichloroethane, 
dry toluene, and dry ethyl acetate were purified by distillation over calcium hydride under an 
argon atmosphere. Deuterated chloroform was filtered through an alumina plug prior to use. 
Reactions were monitored by TLC analysis (pre-coated silica gel 60 F254 plates, 250 µm layer 
thickness) and visualized by using UV lamp (254 nm) and/or a potassium permanganate solution 
(3 g KMnO4 and 4 g K2CO3 in 4 mL 5% NaOH solution and 200 mL H2O). Flash column 
chromatography was performed with 40-63 µm silica gel (Silicycle). Infrared spectra were 
measured on a Smiths Detection IdentifyIR FT-IR spectrometer (ATR). Melting points were 
uncorrected and determined using a Laboratory Devices Mel-Temp II. Mass spectrometry data 
were recorded on a VG-70-70 HF instrument. All NMR data was collected at room temperature 
in CDCl3 on a 400, 500, or 600 MHz Bruker instrument. Chemical shifts (δ) are reported in parts 
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per million (ppm) with internal CHCl3 (δ 7.26 ppm for 1H and 77.00 ppm for 13C).  1H NMR data 
are reported as follows: chemical shift, multiplicity (s = singlet, bs = broad singlet, d = doublet, t 
= triplet, q = quartet, m = multiplet, bm = broad multiplet, dd = doublet of doublets, dt = doublet 
of triplets, td = triplet of doublets, qd = quartet of doublets, sep = septet, app t = apparent triplet), 
integration, and coupling constant(s) (J) in Hertz (Hz). 13C NMR spectra were run using a 
proton-decoupled pulse sequence.  
3.2 EXPERIMENTAL PROCEDURES 
3.2.1 Chapter 1 Experimental 
N
N
O
O
N1-5
 
tert-Butyl 4-(4-methylpyridin-3-yl)piperazine-1-carboxylate (1-5). A microwave vial filled 
with argon was charged with tert-butyl 1-piperazinecarboxylate (252 mg, 1.35 mmol), NaO-t-Bu 
(130 mg, 1.35 mmol), (rac)-BINAP (10.7 mg, 0.017 mmol, 1.5% mol), Pd2(dba)3 (5.2 mg, 
0.0056 mmol, 1% mol in Pd), and degassed toluene (6.8 mL).  3-Bromo-4-methylpyridine (200 
mg, 1.13 mmol) was added, and the mixture was heated in sealed vial under argon at 110 °C for 
40 h.  After cooling to room temperature, the mixture was diluted with CH2Cl2, filtered over a 
Celite pad, and the volatiles were removed under reduced pressure. Chromatography on SiO2 
(70% EtOAc/hexanes) afforded 1-5 as a yellow oil (170 mg, 0.613 mmol, 54%): IR (ATR) 2976, 
2861, 2819, 1693, 1591, 1454, 1416, 1365, 1250, 1235, 1169, 1124, 1037, 1001, 926, 830 cm-1; 
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1H-NMR (400 MHz, CDCl3) δ 8.24 (s, 1 H), 8.21 (d, J = 4.8 Hz, 1 H), 7.09 (d, J = 4.8 Hz, 1 H), 
3.58 (t, J = 4.8 Hz, 4 H), 2.93 (t, J = 4.8 Hz, 4 H), 2.31 (s, 3 H), 1.49 (s, 9 H); 13C-NMR (100 
MHz, CDCl3) δ 154.7, 147.2, 144.8, 141.4 (2 C), 125.7, 79.9, 51.5, 28.4, 17.3; HR-LCMS 
(+ESI) m/z calcd for C15H24N3O2 (M+H) 278.1863, found 278.1857. 
N
N
O
O
Br
1-6
 
tert-Butyl 4-(3-bromo-2-methylphenyl)piperazine-1-carboxylate (1-6).32b  A microwave vial 
filled with argon was charged with tert-butyl 1-piperazinecarboxylate (154 mg, 0.825 mmol), 
NaO-t-Bu (95.2 mg, 0.990 mmol), (rac)-BINAP (39.3 mg, 0.0619 mmol, 7.5% mol), Pd2(dba)3 
(19.2 mg, 0.0206 mmol, 2.5% mol in Pd), and degassed toluene (2.1 mL).  2-Bromo-6-
iodotoluene (121 uL, 0.825 mmol) was then added, and the mixture was heated in sealed vial 
under argon at 80 °C for 19 h.  After cooling to room temperature, the mixture was diluted with 
CH2Cl2, filtered over a Celite pad, and volatiles were evaporated under reduced pressure.  
Chromatography on SiO2 (10% EtOAc/hexanes) afforded 1-6 as a yellow oil (95 mg, 0.267 
mmol, 32%):  1H-NMR (500 MHz, CDCl3) δ 7.30 (d, J = 8.0 Hz, 1 H), 7.02 (t, J = 8.0 Hz, 1 H), 
6.95 (d, J = 7.5 Hz, 1 H), 3.57 (m, 4 H), 2.83 (t, J = 4.5 Hz, 4 H), 2.40 (s, 3 H), 1.49 (s, 9 H). 
N
N
O
O
1-7
 
tert-Butyl 4-(o-tolyl)-1,4-diazepane-1-carboxylate (1-7). A microwave vial filled with argon 
was charged with 1-Boc-homopiperazine (223 mg, 1.10 mmol), NaO-t-Bu (116 mg, 1.20 mmol), 
(rac)-BINAP (47.8 mg, 0.0752 mmol, 7.5% mol), Pd2(dba)3 (23.3 mg, 0.0251 mmol, 2.5% mol 
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in Pd), and degassed toluene (2.8 mL). 2-Bromotoluene (175 mg, 1.00 mmol) was added, and the 
mixture was heated in sealed vial under argon at 80 °C for 19 h. After cooling to room 
temperature, the mixture was diluted with CH2Cl2, filtered over a Celite pad, and the volatiles 
were evaporated under reduced pressure. Chromatography on SiO2 (10% EtOAc/hexanes) 
afforded 1-7 as a yellow oil (139 mg, 0.479 mmol, 48%): IR (ATR) 2973, 2828, 1689, 1598, 
1491, 1457, 1411, 1364, 1233, 1215, 1156, 1122, 878, 761, 725 cm-1; 1H-NMR (500 MHz, 
CDCl3, rt, rotamers) δ 7.16 (d, J = 6.0 Hz, 1 H), 7.12 (d, J = 6.0 Hz, 1 H), 7.04 (d, J = 7.5 Hz, 1 
H), 6.95 (t, J = 7.0 Hz, 1 H), 3.62-3.52 (m, 4 H), 3.12-3.04 (m, 4 H), 2.31 (s, 3 H), 2.00-1.88 (m, 
2 H), 1.49 (s, 9 H); 13C-NMR (100 MHz, CDCl3, rt, rotamers) δ 155.6, 155.5, 153.9, 153.8, 
132.9, 130.9, 126.5, 123.1, 120.8 (2 C), 79.3, 56.2, 56.0, 55.5, 55.2, 48.4, 48.0, 46.2, 45.4, 29.0, 
28.9, 28.5, 18.5; HR-LCMS (+ESI) m/z calcd for C17H27N2O2 (M+H) 291.2067, found 291.2062. 
N
N
H
O
O
1-8
 
tert-Butyl 4-(o-tolylamino)piperidine-1-carboxylate (1-8). A microwave vial filled with 
nitrogen was charged with the 4-amino-1-Boc-piperidine (409 mg, 2.04 mmol), NaO-t-Bu (202 
mg, 2.04 mmol), (rac)-BINAP (16.2 mg, 0.0255 mmol, 1.5% mol), Pd2(dba)3 (7.8 mg, 0.0085 
mmol, 1% mol in Pd), and degassed toluene (3.0 mL).  2-Bromotoluene (297 mg, 1.70 mmol) 
was added, and the mixture was heated in sealed vial under argon at 110 °C for 24 h. After 
cooling to room temperature, the mixture was diluted with CH2Cl2, filtered over a Celite pad, and 
the volatiles were evaporated under reduced pressure.  Chromatography on SiO2 (20% 
EtOAc/hexanes) afforded 1-8 as an off-white solid (360 mg, 1.24 mmol, 73%): Mp 85.9-87.5 ºC; 
IR (ATR) 3388, 2926, 2858, 1632, 1604, 1586, 1513, 1448, 1313, 1267, 1239, 1267, 1195, 1129, 
986, 911, 747 cm-1; 1H-NMR (400 MHz, CDCl3) δ 7.11 (app t, J = 7.6 Hz, 1 H), 7.06 (d, J = 7.2 
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Hz, 1 H), 6.67-6.61 (m, 2 H), 4.04 (bs, 2 H), 3.52-3.41 (m, 1 H), 3.37-3.32 (m, 1 H), 2.96 (app t, 
J = 11.6 Hz, 2 H), 2.12 (s, 3H), 2.10-2.02 (m, 2 H), 1.47 (s, 9 H), 1.42-1.31 (m, 2 H); 13C-NMR 
(100 MHz, CDCl3) δ 154.7, 144.6, 130.4, 127.1, 121.9, 116.9, 110.3, 79.5, 49.8, 42.6, 32.5, 28.4, 
17.5; HR-LCMS (+ESI) m/z calcd for C17H27N2O2 (M+H) 291.2067, found 291.2062. 
N
H
N
1-9  
N,N’-Dimethyl-N-(o-tolyl)ethane-1,2-diamine (1-9).89 A microwave vial filled with argon was 
charged with the N,N’-dimethylethylenediamine (180 mg, 2.04 mmol), NaO-t-Bu (202 mg, 2.04 
mmol), (rac)-BINAP (16.2 mg, 0.026 mmol, 1.5% mol), Pd2(dba)3 (7.8 mg, 0.0085 mmol, 1% 
mol in Pd), and degassed toluene (10.2 mL). 2-Bromotoluene (297 mg, 1.70 mmol) was then 
added, and the mixture was heated in sealed vial under argon at 110 °C for 24 h. After cooling to 
room temperature, the mixture was diluted with CH2Cl2, filtered over a Celite pad, and the 
volatiles were evaporated under reduced pressure. Chromatography on basic Al2O3 (5% 
MeOH/CH2Cl2) afforded 1-9 as a brown oil (50.8 mg 0.285 mmol, 17%):  1H-NMR (400 MHz, 
CDCl3) δ 7.16 (t, J = 7.6 Hz, 2 H), 7.08 (d, J = 7.6 Hz, 1 H), 6.98 (d, J = 7.2 Hz, 1 H), 3.05 (t, J 
= 6.4 Hz, 2 H), 2.71 (t, J = 6.4 Hz, 2 H), 2.65 (s, 3 H), 2.43 (s, 3 H), 2.32 (s, 3 H), 1.36 (bs, 1 H); 
HR-LCMS (+ESI) m/z calcd for C11H19N2 (M+H) 179.1543, found 179.1541.  
N
O
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Br
1-10
 
1-(4-(3-Bromo-2-methylphenyl)piperazin-1-yl)-2-(((3,5-dimethylisoxazol-4-yl)methyl)thio) 
ethan-1-one (1-10).  A solution of 1-6 (77.0 mg, 0.217 mmol) in THF (0.3 mL) was cooled to 0 
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ºC, treated with 4N HCl in dioxanes (1.3 mL) and stirred at 0 ºC for 2 h. The yellow solid was 
filtered off from the solution, washed with ether, dried and carried crude on to the next step. 
To a solution of ([(3,5-dimethylisoxazol-4-yl)methyl]thio)acetic acid (1-1, 35.0 mg, 0.174 mmol) 
in CH2Cl2 (1.7 mL) was added 4-(3-bromo-2-methylphenyl)piperazine HCl salt and 
triethylamine (121 μL, 0.870 mmol).  The mixture was cooled to 0 °C and T3P (50% solution in 
EtOAc, 184 μL, 0.261 mmol) was added. The reaction mixture was allowed to warm to room 
temperature, stirred for 20 h, diluted with CH2Cl2, and washed with sat. NH4Cl solution, sat. 
NaHCO3 solution, and brine. The organic portion was dried (Na2SO4), filtered, and concentrated 
to give a brown oil.  The crude material was purified by chromatography on SiO2 (60% 
EtOAc/hexanes, base washed with 0.1% NEt3 prior to use) to give 1-10 as a clear colorless oil 
(76.2 mg, 0.174 mmol, 100%, 100% pure by ELSD):  IR (ATR) 2921, 2820, 1637, 1587, 1562, 
1460, 1428, 1282, 1237, 1195, 1136, 1038, 994, 913, 780, 731, 714 cm-1; 1H-NMR (400 MHz, 
CDCl3) δ 7.32 (dd, J = 0.8, 7.6 Hz, 1 H), 7.03 (t, J = 8.0 Hz, 1 H), 6.94 (dd, J = 0.8, 8.0 Hz, 1 H), 
3.77 (bs, 2 H), 3.63 (s, 2 H), 3.63-3.57 (m, 2 H), 3.23 (s, 2 H), 2.90 (t, J = 4.4 Hz, 2 H), 2.88-
2.83 (m, 2 H), 2.43 (s, 3 H), 2.40 (s, 3 H), 2.31 (s, 3 H); 13C-NMR (125 MHz, CDCl3) δ 167.6, 
166.8, 159.7, 152.2, 132.9, 128.1, 127.4, 126.6, 118.3, 109.7, 52.1, 51.8, 46.8, 42.2, 32.1, 23.8, 
18.2, 11.1, 10.2; HR-LCMS (+ESI) m/z calcd for C19H25N3O2BrS (M+H) 438.0845, found 
438.0831. 
N
O
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1-11
 
2-(((3,5-Dimethylisoxazol-4-yl)methyl)thio)-1-(4-(o-tolyl)-1,4-diazepan-1-yl)ethan-1-one (1-
11).  A solution of 1-7 (75.0 mg, 0.258 mmol) in THF (0.3 mL) was cooled to 0 ºC, treated with 
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4N HCl in dioxanes (1.6 mL) and stirred at 0 ºC for 2 h. The solution was concentrated in vacuo 
and the yellow solid was precipitated in ether, filtered off from the solution, washed with ether, 
dried and carried crude on to the next step. 
To a solution of 1-1 (46.0 mg, 0.229 mmol) in CH2Cl2 (2.3 mL) was added 4-(o-tolyl)-1,4-
diazepane HCl salt and triethylamine (159 μL, 1.14 mmol).  The mixture was cooled to 0 °C and 
T3P (50% solution in EtOAc, 242 μL, 0.343 mmol) was added. The reaction mixture was 
allowed to warm to room temperature, stirred for 20 h, diluted with CH2Cl2, and washed with sat. 
NH4Cl solution, sat. NaHCO3 solution, and brine. The organic portion was dried (Na2SO4), 
filtered, and concentrated to give a brown oil.  The crude material was purified by 
chromatography on SiO2 (60% EtOAc/hexanes, base washed with 0.1% NEt3 prior to use) to 
give 1-11 as a clear colorless oil (85.4 mg, 0.229 mmol, 100%, 100% pure by ELSD):  IR (ATR) 
2945, 2825, 1634, 1598, 1491, 1447, 1423, 1215, 1194, 1136, 915, 762, 726 cm-1; 1H-NMR (400 
MHz, CDCl3, rt, rotamers) δ 7.20 (app. d, J = 7.6 Hz, 1 H), 7.17 (app. t, J = 7.6 Hz, 1 H), 7.05 
(app. d, J = 7.6 Hz, 1 H), 7.01 (app. td, J = 2.0, 7.2 Hz, 1 H), 3.82-3.78 (m, 2 H), 3.71-3.65 (m, 4 
H), 3.24-3.20 (m, 3 H), 3.15 (t, J = 5.2 Hz, 1 H), 3.12-3.07 (m, 2 H), 2.46 (app s, 3 H), 2.32 (2 × 
s, 6 H), 2.04 (sept, J = 6.0 Hz, 2 H); 13C-NMR (125 MHz, CDCl3, rt, rotamers) δ 168.9, 168.8, 
166.9, 166.8, 159.8 (2 C), 153.4, 153.3, 132.9 (2 C), 131.1 (2 C), 126.7, 126.6, 123.6, 123.4, 
120.8, 120.7, 109.9, 56.4, 55.8, 55.5, 54.9, 50.1, 47.6, 47.2, 44.9, 32.2, 32.0, 29.5, 28.2, 23.7, 
18.5 (2 C), 11.1, 10.2 (2 C); HR-LCMS (+ESI) m/z calcd for C20H28N3O2S (M+H) 374.1897, 
found 374.1883. 
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2-(((3,5-Dimethylisoxazol-4-yl)methyl)thio)-1-(4-(o-tolylamino)piperidin-1-yl)ethan-1-one 
(1-12).  A solution of 1-8 in MeOH  (0.5 mL) was cooled to 0 ºC, treated with 4N HCl in 
dioxanes (3.0 mL) and stirred at 0 ºC for 30 min and at room temperature for 30 min. The white 
solid was filtered off from the solution, washed with ether, dried and carried crude on to the next 
step. 
To a solution of 1-1 (75.8 mg, 0.377 mmol) in CH2Cl2 (3.8 mL) was added 4-(o-
tolylamino)piperidine HCl salt (103 mg, 0.452 mmol) and triethylamine (262 μL, 1.88 mmol). 
The mixture was cooled to 0 °C and T3P (50% solution in EtOAc, 399 μL, 0.565 mmol) was 
added. The reaction mixture was allowed to warm to room temperature, stirred for 20 h, diluted 
with CH2Cl2, and washed with sat. NH4Cl solution, sat. NaHCO3 solution, and brine. The organic 
portion was dried (Na2SO4), filtered, and concentrated to give a brown oil.  The crude material 
was purified by chromatography on SiO2 (60% EtOAc/hexanes, base washed with 0.1% NEt3 
prior to use) to give 1-12 as a clear colorless oil (131 mg, 0.351 mmol, 93%, 100% pure by 
ELSD):  IR (ATR) 3388, 2926, 2858, 1632, 1604, 1586, 1513, 1448, 1313, 1267, 1195, 1129, 
986, 911, 747 cm-1; 1H-NMR (400 MHz, CDCl3) δ 7.12 (td, J = 1.2, 7.6 Hz, 1 H), 7.07 (d, J = 
7.2 Hz, 1 H), 6.67 (td, J = 1.2, 7.6 Hz, 1 H), 6.63 (d, J = 8.0 Hz, 1 H), 4.48-4.40 (m, 1 H), 3.81-
3.73 (m, 1 H), 3.62 (s, 2 H), 3.62-3.53 (m, 1 H), 3.36 (bs, 1 H), 3.28-3.18 (m, 3 H), 2.98-2.90 (m, 
1 H), 2.43 (s, 3 H), 2.30 (s, 3 H), 2.20-2.10 (m, 5 H), 1.52-1.32 (m, 2 H); 13C-NMR (125 MHz, 
CDCl3) δ 167.4, 166.8, 159.7, 144.4, 130.5, 127.1, 122.1, 117.2, 110.2, 109.9, 49.5, 45.3, 40.9, 
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32.8, 32.2, 23.8, 17.5, 11.1, 10.2; HR-LCMS (+ESI) m/z calcd for C20H28N3O2S (M+H) 
374.1897, found 374.1891. 
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1-13
 
2-(((3,5-Dimethylisoxazol-4-yl)methyl)thio)-1-(4-(4-methylpyridin-3-yl)piperazin-1-yl) 
ethan-1-one (1-13).  A solution of 1-5 in THF (0.3 mL) was cooled to 0 ºC, treated with 4N HCl 
in dioxanes (1.4 mL) and stirred at 0 ºC for 1 h and at room temperature for 2 h. The yellow solid 
was filtered off from the solution, washed with ether, dried and carried crude on to the next step. 
To a solution of  1-1 (45.0 mg, 0.224 mmol) in CH2Cl2 (2.2 mL) was added 1-(4-methylpyridin-
3-yl)piperazine HCl salt and triethylamine (155 μL, 1.12 mmol).  The mixture was cooled to 0 
°C and T3P (50% solution in EtOAc, 237 μL, 0.335 mmol) was added. The reaction mixture was 
allowed to warm to room temperature, stirred for 20 h, diluted with CH2Cl2, and washed with sat. 
NH4Cl solution, sat. NaHCO3 solution, and brine. The organic portion was dried (Na2SO4), 
filtered, and concentrated to give a light brown oil. The crude material was purified by 
chromatography on SiO2 (70% acetone/hexanes, base washed with 0.1% NEt3 prior to use) to 
give 1-13 as an off white solid (61.0 mg, 0.169 mmol, 76%, 100% pure by ELSD):  Mp 154.3-
155.5 ºC; IR (ATR) 2918, 2821, 1638, 1591, 1438, 1279, 1235, 1202, 1139, 1139, 1033, 831, 
736 cm-1; 1H-NMR (400 MHz, CDCl3) δ 8.24-8.21 (m, 2 H), 7.10 (d, J = 4.8 Hz, 1 H), 3.76 (t, J 
= 4.8 Hz, 2 H), 3.62 (s, 2 H), 3.60 (t, J = 4.8 Hz, 2 H), 3.23 (s, 2 H), 3.02 (t, J = 4.8 Hz, 2 H), 
2.95 (t, J = 4.8 Hz, 2 H), 2.42 (s, 3 H), 2.32 (s, 3 H), 2.29 (s, 3 H); 13C-NMR (125 MHz, CDCl3) 
δ 167.6, 166.8 159.7, 146.7, 145.2, 141.5, 141.4, 125.8, 109.7, 51.5, 51.4, 46.8, 42.2, 32.0, 23.8, 
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17.3, 11.1, 10.2; HR-LCMS (+ESI) m/z calcd for C18H25N4O2S (M+H) 361.1693, found 
361.1680. 
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1-(4-(5-Chloro-2-methylphenyl)piperazin-1-yl)-2-(((3,5-dimethylisoxazol-4-yl)methyl)thio) 
ethan-1-one (1-14).  To a solution of 1-1 (45.0 mg, 0.224 mmol) in CH2Cl2 (2.2 mL) was added 
1-(5-chloro-2-methylphenyl)piperazine (56.5 mg, 0.268 mmol) and triethylamine (93.2 μL, 0.671 
mmol).  The mixture was cooled to 0 °C and T3P (50% solution in EtOAc, 237 μL, 0.335 mmol) 
was added. The reaction mixture was allowed to warm to room temperature, stirred for 20 h, 
diluted with CH2Cl2, and washed with sat. NH4Cl solution, sat. NaHCO3 solution, and brine. The 
organic portion was dried (Na2SO4), filtered, and concentrated to give a brown oil. The crude 
material was purified by chromatography on SiO2 (50% EtOAc/hexanes, base washed with 0.1% 
NEt3 prior to use) to give 1-14 as a clear colorless oil (88.1 mg, 0.224 mmol, 100%, 99.9% pure 
by ELSD):  IR (ATR) 2921, 2818, 1635, 1592, 1489, 1438, 1270, 1224, 1195, 1148, 1039, 924, 
910, 818, 728 cm-1; 1H-NMR (400 MHz, CDCl3) δ 7.11 (d, J = 8.0 Hz, 1 H), 6.99 (dd, J = 2.0, 
8.0 Hz, 1 H), 6.94 (d, J = 2.4 Hz, 1 H), 3.76 (t, J = 4.4 Hz, 2 H), 3.63 (s, 2 H), 3.59 (t, J = 4.8 Hz, 
2 H), 3.23 (s, 2 H), 2.91 (t, J = 4.8 Hz, 2 H), 2.86 (t, J = 4.8 Hz, 2 H), 2.43 (s, 3 H), 2.30 (s, 3 H), 
2.27 (s, 3 H); 13C-NMR (125 MHz, CDCl3) δ 167.6, 166.8, 159.7, 151.7, 132.1, 131.8, 130.9, 
123.7, 119.7, 109.7, 51.6, 51.5, 46.8, 42.2, 32.0, 23.7, 17.4, 11.1, 10.2; HR-LCMS (+ESI) m/z 
calcd for C19H25N3O2ClS (M+H) 394.1351, found 394.1340. 
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2-(((3,5-Dimethylisoxazol-4-yl)methyl)thio)-N-methyl-N-(2-(methyl(o-tolyl)amino)ethyl) 
acetamide (1-15).  To a solution of 1-1 (60.8 mg, 0.302 mmol) in CH2Cl2 (3.0 mL) was added 1-
9 (50.0 mg, 0.275 mmol) and triethylamine (115 μL, 0.825 mmol).  The mixture was cooled to 0 
°C and T3P (50% solution in EtOAc, 292 μL, 0.412 mmol) was added. The reaction was allowed 
to warm to room temperature, stirred for 20 h, diluted with CH2Cl2, and washed with sat. NH4Cl 
solution, sat. NaHCO3 solution, and brine. The organic portion was dried (Na2SO4), filtered, and 
concentrated to give a brown oil. The crude material was purified by chromatography on SiO2 
(60% EtOAc/hexanes, base washed with 0.1% NEt3 prior to use) to give 1-15 as a light yellow 
oil (75.2 mg, 0.207 mmol, 75%, 99.6% pure by ELSD):  IR (ATR) 2932, 2795, 1640, 1598, 
1493, 1451, 1421, 1393, 1196, 1108, 1047, 766, 738 cm-1; 1H-NMR (400 MHz, CDCl3, rt, 
rotamers) δ 7.20-7.12 (m, 2 H), 7.08-6.94 (m, 2 H), 3.58 (d, J = 5.6 Hz, 2 H), 3.54 (t, J = 6.8 Hz, 
1 H), 3.39 (t, J = 6.4 Hz, 1 H), 3.16-3.08 (m, 3 H), 2.97 and 2.95 (2 × s, 4 H), 2.71 and 2.67 (2 × 
s, 3 H), 2.38 (s, 3 H), 2.30 (s, 2 H), 2.28-2.25 (m, 4 H), (signals for these rotamers coalesced in 
DMSO-d6 @ 357 K); 13C-NMR (125 MHz, CDCl3, rt, rotamers) δ 169.2, 168.8, 166.7 (2 C), 
159.7, 151.7, 150.8, 133.8, 132.9, 131.4, 131.2, 126.7, 126.5, 124.0, 123.2, 120.2, 119.9, 109.8, 
53.9, 53.2, 48.4, 46.4, 43.3, 42.3, 36.7, 33.8, 32.4, 31.6, 23.7, 23.4, 18.2, 18.0, 11.0 (2 C), 10.1, 
(signals for these rotamers coalesced in DMSO-d6 @ 357 K); HR-LCMS (+ESI) m/z calcd for 
C19H28N3O2S (M+H) 362.1897, found 362.1890. 
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2-(((3,5-Dimethylisoxazol-4-yl)methyl)thio)-1-(4-(2-fluorophenyl)piperazin-1-yl)ethan-1-
one (1-16).  To a solution of 1-1 (75.8 mg, 0.377 mmol) in CH2Cl2 (3.8 mL) was added 1-(2-
fluorophenyl)-piperazine (81.4 mg, 0.452 mmol) and triethylamine (262 μL, 1.88 mmol).  The 
mixture was cooled to 0 °C and T3P (50% solution in EtOAc, 399 μL, 0.565 mmol) was added. 
The reaction was allowed to warm to room temperature, stirred for 20 h, diluted with CH2Cl2, 
and washed with sat. NH4Cl solution, sat. NaHCO3 solution, and brine.  The organic portion was 
dried (Na2SO4), filtered, and concentrated to give a light brown oil. The crude material was 
purified by chromatography on SiO2 (60% EtOAc/hexanes, base washed with 0.1% NEt3 prior to 
use) to give 1-16 as a slight yellow oil (134 mg, 0.369 mmol, 98%, 100% pure by ELSD):  IR 
(ATR) 2918, 2827, 1636, 1613, 1500, 1439, 1237, 1195, 1147, 1031, 909, 811, 753, 725 cm-1; 
1H-NMR (400 MHz, CDCl3) δ 7.10-6.90 (m, 4 H), 3.79 (t, J = 5.2 Hz, 2 H), 3.63-3.59 (m, 4 H), 
3.23 (s, 2 H), 3.10 (t, J = 4.8 Hz, 2 H), 3.05 (t, J = 5.2 Hz, 2 H), 2.28 (s, 3 H), 2.42 (s, 3 H); 13C-
NMR (125 MHz, CDCl3) δ 167.5, 166.8, 159.7, 155.7 (d, J = 245.0 Hz), 139.4 (d, J = 8.8 Hz), 
124.5 (d, J = 3.8 Hz), 123.3 (d, J = 8.8 Hz), 119.2 (d, J = 2.5 Hz), 116.3 (d, J = 20.0 Hz), 109.7, 
50.7 (d, J = 2.5 Hz), 50.3 (d, J = 2.5 Hz), 46.6, 41.9, 32.1, 23.7, 11.1, 10.2; HR-LCMS (+ESI) 
m/z calcd for C18H23N3O2FS (M+H) 364.1490, found 364.1474. 
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2-Chloro-1-(4-(o-tolyl)piperazin-1-yl)ethan-1-one (1-3).90 To a solution of chloroacetyl 
chloride (0.698 g, 6.05 mmol) and potassium carbonate (1.14 g, 8.25 mmol) in THF (7.0 mL) 
was added 1-(2-methylphenyl)piperazine (1.00 g, 5.50 mmol) in THF (12.6 mL) at 0 °C. The 
reaction was gradually warmed to room temperature and stirred for 16 h.  The crude was diluted 
with water, extracted with EtOAc (3 × 20 mL), and the combined organic extracts were washed 
sequentially with sat. NaHCO3 solution, 0.1 N aqueous HCl, and brine, dried (Na2SO4), filtered 
and concentrated. The crude solid was filtered through a plug of SiO2 (pretreated with 0.1% NEt3 
in 30% EtOAc/hexanes) and washed thoroughly with 30% EtOAc/hexanes to give 1-3 as an off 
white solid (1.37 g, 5.42 mmol, 99%):  1H-NMR (400 MHz, CDCl3) δ 7.22-7.16 (m, 2 H), 7.05-
6.99 (m, 2 H), 4.12 (s, 2 H), 3.78 (t, J = 4.8 Hz, 2 H), 3.67 (t, J = 4.8 Hz, 2 H), 2.97 (t, J = 5.2 
Hz, 2 H), 2.91 (t, J = 4.8 Hz, 2 H), 2.33 (s, 3 H). 
OH
O
O
1-17  
Methyl 4-(hydroxymethyl)benzoate (1-17).91  4-Hydroxymethylbenzoic acid (1.09 g, 6.57 
mmol) was dissolved in MeOH (30 mL), acidified with conc. HCl (3 mL), and heated at reflux 
for 4 h. After cooling, the reaction mixture was neutralized with NEt3 to pH 7 and evaporated. 
The crude residue was dissolved in CH2Cl2 (20 mL) and washed with a 5% NaHCO3 solution (2 
× 20 mL).  The organic layer was separated, dried (Na2SO4), and evaporated to yield 1-17 as an 
off white solid (926 mg, 5.57 mmol, 78%):  1H-NMR (400 MHz, CDCl3) δ 8.04 (dd, J = 1.6, 8.4 
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Hz, 2 H), 7.44 (app. d, J = 8.4 Hz, 2 H), 4.78 (d, J = 6.0 Hz, 2 H), 3.92 (s, 3 H), 1.74 (t, J = 6.0 
Hz, 1 H). 
S OH
1-18  
Thiophen-2-ylmethanol (1-18).92  To a solution of 2-thiophenecarbaldehyde (0.500 g, 4.46 
mmol) in MeOH (41 mL) at 0 ºC was added NaBH4 (0.506 g, 13.4 mmol). The mixture was 
stirred for 3 h, after which water (50 mL) was added. After 30 min, the MeOH was evaporated 
and the reaction mixture was extracted with CH2Cl2 (3 × 50 mL), dried (Na2SO4), and 
concentrated.  The crude brown oil, 1-18, was used without further purification (0.468 g, 4.10 
mmol, 92%): 1H-NMR (400 MHz, CDCl3) δ 7.29-7.26 (m, 1 H), 7.02-6.97 (m, 2 H), 4.83 (d, J = 
4.4 Hz, 2 H), 1.81 (m, 1 H). 
S OH
1-19  
(5-Methylthiophen-2-yl)methanol (1-19).93  To a solution of 5-methyl-2-
thiophenecarbaldehyde (0.500 g, 3.96 mmol) in MeOH (36 mL) at 0 ºC was added NaBH4 
(0.450 g, 11.9 mmol). The reaction mixture was stirred for 3 h, water (50 mL) was added, and it 
was stirred for 30 min. The MeOH was evaporated and the crude residue was extracted with 
CH2Cl2 (3 × 50 mL), dried (Na2SO4), and concentrated. The brown oil, 1-19, was used without 
further purification (508 mg, 3.96 mmol, 100%):  1H-NMR (400 MHz, CDCl3) δ 6.79 (app. d, J 
= 3.2 Hz, 1 H), 6.62-6.61 (m, 1 H), 4.73 (d, J = 6.0 Hz, 2 H), 2.47 (s, 3 H), 1.69 (bs, 1 H). 
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(3,5-Dimethylisoxazol-4-yl)methanol (1-2).94  To a solution of 3,5-dimethylisoxazole-4-
carboxylic acid (1.60 g, 11.3 mmol) in THF (69.4 mL) at 0 ºC was added a 2 M solution of 
LiAlH4 in THF (5.60 mL) dropwise.  The solution was allowed to warm to room temperature and 
stirred overnight.  The resultant slurry was transferred to a 500 mL erlenmeyer flask and sodium 
sulfate decahydrate was added until the foaming subsided.  Celite (2.3 g) was added and the 
slurry was filtered, washed with CH2Cl2 (75 mL), and the filtrate was concentrated to give 1-2 as 
a clear colorless oil (1.14 g, 8.97 mmol, 80%):  1H-NMR (400 MHz, CDCl3) δ 4.46 (s, 2 H), 2.38 
(s, 3 H), 2.29 (s, 3 H), 1.63 (bs, 1 H).  
N
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Methyl 4-((2-oxo-2-(4-(o-tolyl)piperazin-1-yl)ethoxy)methyl)benzoate (1-20).  A solution of 
1-17 (69.0 mg, 0.415 mmol) in THF (0.50 mL) was cooled to 0 ºC and a 60% dispersion in 
mineral oil of NaH (17.4 mg, 0.435 mmol) was added. The resultant slurry was stirred at 0 ºC for 
15 min, then room temperature for 15 min, cooled to 0 ºC and a solution of 1-3 (100 mg, 0.396 
mmol) in THF (0.29 mL) was added dropwise. The mixture was allowed to warm to room 
temperature, stirred for 24 h, quenched with water (1 mL), diluted with EtOAc (15 mL) and 
water (5 mL), and extracted with EtOAc (2 × 15 mL). The combined organic layers were washed 
with brine, dried (Na2SO4) and concentrated. The residue was purified by chromatography on 
SiO2 (45% EtOAc/hexanes, column base washed with 0.1% NEt3 prior to use) to yield 1-20 as a 
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slight yellow oil (51.9 mg, 0.136 mmol, 34%, 100% pure by ELSD):  IR (ATR) 2950, 1719, 
1650, 1493, 1436, 1276, 1225, 1109, 1020, 974, 759, 724 cm-1; 1H-NMR (400 MHz, CDCl3) δ 
8.04 (d, J = 8.0 Hz, 2 H), 7.45 (d, J = 8.0 Hz, 2 H), 7.21-7.14 (m, 2 H), 7.11 (t, J = 7.2 Hz, 1 H), 
6.95 (d, J = 7.6 Hz, 1 H), 4.69 (s, 2 H), 4.27 (s, 2 H), 3.92 (s, 3 H), 3.77 (m, 2 H), 3.63 (app. t, J 
= 4.4 Hz, 2 H), 2.91-2.85 (m, 4 H), 2.32 (s, 3 H); 13C-NMR (125 MHz, CDCl3) δ 167.5, 166.9, 
150.7, 142.5, 132.7, 131.2, 129.8, 129.7, 127.5, 126.7, 123.8, 119.2, 72.6, 69.7, 52.1, 52.0, 51.7, 
45.6, 42.4, 17.8; HR-LCMS (+ESI) m/z calcd for C22H27N2O4 (M+H) 383.1965, found 383.1963. 
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2-((3,5-Dimethylisoxazol-4-yl)methoxy)-1-(4-(o-tolyl)piperazin-1-yl)ethan-1-one (1-21). A 
solution of 1-2 (30.2 mg, 0.237 mmol) in THF (0.48 mL) was cooled to 0 ºC and a 60% 
dispersion in mineral oil of NaH (19.0 mg, 0.475 mmol) was added. The resultant slurry was 
stirred at 0 ºC for 30 min and 1-3 (60.0 mg, 0.237 mmol) was added. The mixture was allowed to 
warm to room temperature, stirred for 20 h, quenched with brine (1 mL), diluted with EtOAc (15 
mL) and brine (5 mL), and extracted with EtOAc (2 × 15 mL). The combined organic layers 
were dried (Na2SO4), and concentrated. The residue was purified by chromatography on SiO2 
(60% EtOAc/hexanes) to yield 1-21 as a light yellow oil (73.5 mg, 0.214 mmol, 90%, 100% pure 
by ELSD):  IR (ATR) 2918, 2817, 1645, 1599, 1493, 1443, 1369, 1273, 1225, 1116, 1030, 977, 
764, 725 cm-1; 1H-NMR (400 MHz, CDCl3) δ 7.22-7.15 (m, 2 H), 7.02 (td, J = 1.2, 7.6 Hz, 1 H), 
6.97 (app. d, J = 8.0 Hz, 1 H), 4.41 (s, 2 H), 4.17 (s, 2 H), 3.77 (m, 2 H), 3.59 (t, J = 4.8 Hz, 2 
H), 2.89 (app. t, J = 3.6 Hz, 4 H), 2.41 (s, 3 H), 2.32 (s, 3 H), 2.30 (s, 3 H); 13C-NMR (125 MHz, 
CDCl3) δ 167.8, 167.5, 159.8, 150.7, 132.7, 131.2, 126.7, 123.9, 119.2, 110.5, 68.7, 61.7, 52.1, 
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51.7, 45.6, 42.3, 17.8, 11.1, 10.1; HR-LCMS (+ESI) m/z calcd for C19H26N3O3 (M+H) 344.1969, 
found 344.1960. 
N
N
O
O
S
1-22
 
2-(Thiophen-2-ylmethoxy)-1-(4-(o-tolyl)piperazin-1-yl)ethan-1-one (1-22). A solution of 1-18 
(32.5 mg, 0.285 mmol) in THF (0.48 mL) was cooled to 0 ºC and a 60% dispersion in mineral oil 
of NaH (19.0 mg, 0.475 mmol) was added. The resultant slurry was stirred at 0 ºC for 30 min 
and 1-3 (60.0 mg, 0.237 mmol) was added. The mixture was allowed to warm to room 
temperature, stirred for 18 h, quenched with brine (1 mL), diluted with EtOAc (15 mL) and brine 
(5 mL), and extracted with EtOAc (2 × 15 mL). The combined organic layers were dried 
(Na2SO4) and concentrated. The residue was purified twice by chromatography on SiO2 (50% 
EtOAc/hexanes then 24% acetone/hexanes) to yield 1-22 as a light yellow oil (54.9 mg, 0.166 
mmol, 70%, 100% pure by ELSD):  IR (ATR) 3067, 2911, 2857, 2817, 1646, 1599, 1493, 1441, 
1274, 1224, 1150, 1113, 1030, 976, 763, 722, 705 cm-1; 1H-NMR (400 MHz, CDCl3) δ 7.32 (d, J 
= 5.2 Hz, 1 H), 7.22-7.14 (m, 2 H), 7.08-6.95 (m, 4 H), 4.80 (s, 2 H), 4.23 (s, 2 H), 3.76 (m, 2 
H), 3.62 (t, J = 4.4 Hz, 2 H) 2.89 (t, J = 4.8 Hz, 4 H), 2.32 (s, 3 H); 13C-NMR (125 MHz, CDCl3) 
δ 167.5, 150.8, 139.6, 132.7, 131.1, 127.3, 126.8, 126.6, 126.4, 123.7, 119.2, 69.0, 67.3, 52.0, 
51.7, 45.7, 42.3, 17.8; HR-LCMS (+ESI) m/z calcd for C18H23N2O2S (M+H) 331.1475, found 
331.1465.  
 
 
 
 62 
N
N
O
O
S
1-23
 
2-((5-Methylthiophen-2-yl)methoxy)-1-(4-(o-tolyl)piperazin-1-yl)ethan-1-one (1-23). A 
solution of 1-19 (36.5 mg, 0.285 mmol) in THF (0.48 mL) was cooled to 0 ºC and was treated 
with a 60% dispersion in mineral oil of NaH (19.0 mg, 0.475 mmol). The resultant slurry was 
stirred at 0 ºC for 30 min and 1-3 (60.0 mg, 0.237 mmol) was added. The mixture was allowed to 
warm to room temperature, stirred for 12.5 h, quenched with brine (1 mL), diluted with EtOAc 
(15 mL) and brine (5 mL), and extracted with EtOAc (2 × 15 mL). The combined organic layers 
were dried (Na2SO4) and concentrated. The residue was purified by chromatography on SiO2 
(24% acetone/hexanes) to yield 1-23 as a light yellow oil (28.9 mg, 0.0839 mmol, 35%, 100% 
pure by ELSD):  IR (ATR) 2916, 2857, 2817, 1648, 1599, 1493, 1443, 1274, 1224, 1152, 1113, 
1030, 975, 802, 763, 724 cm-1; 1H-NMR (400 MHz, CDCl3) δ 7.22-7.14 (m, 2 H), 7.05-6.95 (m, 
2 H), 6.83 (d, J = 3.2 Hz, 1 H), 6.64-6.61 (m, 1 H), 4.70 (s, 2 H), 4.21 (s, 2 H), 3.76 (m, 2 H), 
3.63 (t, J = 4.8 Hz, 2 H), 2.89 (t, J = 5.2 Hz, 4 H), 2.47 (d, J = 0.8 Hz, 3 H), 2.32 (s, 3 H); 13C-
NMR (125 MHz, CDCl3) δ 167.6, 150.8, 141.2, 137.2, 132.7, 131.1, 127.6, 126.6, 124.8, 123.7, 
119.2, 68.8, 67.5, 52.0, 51.7, 45.7, 42.3, 17.8, 15.4; HR-LCMS (+ESI) m/z calcd for 
C19H25N2O2S (M+H) 345.1631, found 345.1623. 
N
N
S
O
O
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1-24
 
1-(((Phenylthio)methyl)sulfonyl)-4-(o-tolyl)piperazine (1-24). To a solution of 1-(2-
methylphenyl)piperazine (0.500 g, 2.75 mmol) and triethylamine (0.390 mL, 2.75 mmol) in 
 63 
CH2Cl2 (9.8 mL) at 0 ºC was added chloromethanesulfonyl chloride (0.460 g, 3.03 mmol). The 
reaction mixture was stirred at 0 ºC and was gradually warmed to room temperature.  After 14 h, 
the reaction mixture was quenched with sat. NH4Cl solution (3 mL), and extracted with EtOAc 
(3 × 20 mL).  The combined organic extracts were washed water (2 × 10 mL) and brine (10 mL), 
dried (Na2SO4), filtered, and concentrated. The crude solid was filtered through a plug of SiO2 
(pretreated with 0.1% NEt3 in 30% EtOAc/hexanes) and washed thoroughly with 30% 
EtOAc/hexanes to give 1-4 (676 mg, 2.34 mmol, 85%) as an orange solid:  1H-NMR (400 MHz, 
CDCl3) δ 7.21-7.17 (m, 2 H), 7.05-7.00 (m, 2 H), 4.57 (s, 2 H), 3.63 (t, J = 4.8 Hz, 4 H), 2.98 (t, 
J = 5.2 Hz, 4 H), 2.31 (s, 3 H). 
A solution of thiophenol (61.0 mg, 0.554 mmol), 1-4 (40.0 mg, 0.139 mmol) and Cs2CO3 (90.3 
mg, 0.277 mmol) in DMF (0.28 mL) were stirred at 80 ºC for 2 d.  The crude reaction mixture 
was diluted with brine (10 mL) and EtOAc (20 mL), and washed with brine (2 × 10 mL). The 
organic layer was dried (Na2SO4) and concentrated.  The residue was purified by 
chromatography on SiO2 (20% EtOAc/hexanes) yielded 1-24 as a clear colorless oil (25.7 mg, 
0.0709 mmol, 51%): IR (ATR) 3054, 2918, 2823, 1598, 1581, 1493, 1440, 1342, 1324, 1262, 
1225, 1153, 1112, 1070, 954, 765, 744, 725, 691 cm-1; 1H-NMR (500 MHz, CDCl3) δ 7.59 (d, J 
= 7.5 Hz, 2 H), 7.39-7.30 (m, 3 H), 7.21-7.14 (m, 2 H), 7.02 (t, J = 7.5 Hz, 1 H), 6.98 (d, J = 8.0 
Hz, 1 H), 4.33 (s, 2 H), 3.51 (t, J = 4.5 Hz, 4 H), 2.92 (t, J = 4.5 Hz, 4 H), 2.28 (s, 3 H); 13C-
NMR (100 MHz, CDCl3) δ 150.7, 133.4, 132.7, 131.2, 131.1, 129.4, 128.1, 126.7, 123.9, 119.4, 
54.2, 51.8, 46.8, 17.7; HR-LCMS (+ESI) m/z calcd for C18H23N2O2S2 (M+H) 363.1195, found 
363.1190.  
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3.2.2 Chapter 2 Experimental  
O
AcO
NHAc
OAc
AcO
OAc
2-11  
2-Acetamido-2-deoxy-1,3,4,6-tetra-O-acetyl-β-D-glucopyranose (2-11).84  Acetic anhydride 
(7.76 mL, 82.3 mmol) was added to a 100 mL flask and cooled to 0 ºC.  N-Acetyl-D-
glucosamine (0.692 g, 3.13 mmol) and montmorillonite K-10 (2.40 g) were added sequentially 
over 15 min and the reaction mixture was stirred at room temperature for 24 h.  The reaction 
mixture was filtered through a pad of Celite®, rinsed with methyl acetate (100 mL), and the 
filtrate was concentrated.  The resulting orange residue was twice recrystallized from hot 
methanol, filtered, and the crystals were washed with ice-cold diethyl ether (3 × 2 mL) to afford 
2-11 as a white crystalline solid (350 mg, 0.900 mmol, 29%): 1H-NMR (400 MHz, CDCl3) δ 
5.69 (d, J = 8.8 Hz, 1 H), 5.41 (d, J = 9.6 Hz, 1 H), 5.17-5.09 (m, 2 H), 4.33-4.25 (m, 2 H), 4.13 
(dd, J = 2.4, 12.6 Hz, 1 H), 3.78 (ddd, J = 2.4, 4.4, 9.6 Hz, 1 H), 2.12 (s, 3 H), 2.09 (s, 3 H), 2.05 
(s, 3 H), 2.04 (s, 3 H). Note: This compound was commercially available through Alfa Aesar 
(Cat. No. = L09020) and was later purchased for the syntheses of 2-12.  
O
AcO
N
AcO
O
OAc
2-12
 
2,3-Dihydrooxazole-3,4,6-tri-O-acetyl-α-D-glucopyranoside (2-12).85a,85b,86a A solution of 2-11 
(200 mg, 0.514 mmol) in dichloroethane (14.3 mL) in a 50 mL round bottom flask was treated 
with TMSOTf (0.100 mL, 0.539 mmol).  The reaction mixture was stirred at 50 ºC for 35 min, 
cooled, and NEt3 (0.220 mL, 1.54 mmol) was added. After stirring at room temperature for 10 
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min, the solution was passed through a short plug of silica and washed with dichloromethane (25 
mL) and ethyl acetate (15 mL). The solvent was removed under reduced pressure and the crude 
orange oil was purified by chromatography on SiO2 (100% EtOAc, base washed with 1% NEt3) 
giving 2-12 (158 mg, 0.478 mmol, 93%) as a colorless oil:  1H-NMR (400 MHz, CDCl3) δ 5.97 
(d, J = 7.6 Hz, 1 H), 5.27 (t, J = 2.4 Hz, 1 H), 4.93 (app. d, J = 9.2 Hz, 1 H), 4.18-4.13 (m, 3 H), 
3.61 (quint., J = 4.4 Hz, 1 H), 2.12 (s, 3 H), 2.10 (s, 3 H), 2.09 (d, J = 1.6 Hz, 3 H), 2.08 (s, 3 H); 
13C-NMR (100 MHz, CDCl3): δ 170.6, 169.5, 169.2, 166.7, 99.4, 70.4, 68.4, 67.5, 65.0, 63.3, 
20.9, 20.8, 20.7, 14.0. 
O
AcO O
NHAc
AcO
OAc
2-13  
Isopropyl 3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy-β-D-glucopyranoside (2-13).68 A 
solution of 2-12 (0.142 g, 0.424 mmol) and anhydrous CuCl2 (58.0 mg, 0.431 mmol) in 
anhydrous CHCl3 (0.82 mL) in a 2-5 mL conical sealed vessel under argon atmosphere was 
treated with anhydrous 2-propanol (0.134 mL, 1.75 mmol). The reaction mixture was heated at 
62 ºC for 2 h. After cooling to room temperature, the mixture was diluted with acetone (15 mL) 
and sat. NaHCO3 solution (7 mL), filtered through a short plug of Celite® with acetone (20 mL).  
The filtrate was concentrated, coevaporated with toluene and the crude residue was shaken with 
CHCl3 and weakly acidic ion-exchange resin (Amberlite IRC-86, ca 1.5 g). The solution was 
filtered, the solvent was reduced under vacuum, and the residue was chromatographed on SiO2 
(75% EtOAc/hexanes) to give 2-13 (146 mg, 0.375 mmol, 87%) as a colorless solid: 1H-NMR 
(400 MHz, CDCl3) δ 5.51 (d, J = 8.4 Hz, 1 H), 5.41 (dd, J = 9.2, 10.4 Hz, 1 H), 5.03, (app. t, J = 
10.0 Hz, 1 H), 4.84 (d, J = 8.4 Hz, 1 H), 4.24 (dd, J = 5.2, 12.0 Hz, 1 H), 4.11 (dd, J = 2.4, 12.0 
Hz, 1 H), 3.93 (sept, J = 6 Hz, 1 H), 3.73-3.60 (m, 2 H), 2.07 (s, 3 H), 2.02 (s, 3 H), 2.02 (s, 3 H), 
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1.94 (s, 3 H), 1.22 (d, J = 6.0 Hz, 3 H), 1.13 (d, J = 6.4 Hz, 3 H); 13C-NMR (100 MHz, CDCl3): δ 
170.8, 170.7, 170.2, 169.5, 99.1, 72.6, 72.1, 71.5, 68.9, 62.3, 55.5, 23.3, 23.2, 21.9, 20.8, 20.7, 
20.6; HRMS (+ESI-TOF) calcd for C17H28NO9 (M+H) 390.1764, found 390.1742. 
O
AcO O
NHAc
AcO
OAc
2-14
 
Cyclohexyl 3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy-β-D-glucopyranoside (2-14).68,95 A 
solution of 2-12 (0.099 g, 0.301 mmol) and anhydrous CuCl2 (41.0 mg, 0.301 mmol) in 
anhydrous CHCl3 (0.68 mL) in a 2-5 mL conical sealed vessel under argon atmosphere was 
treated with cyclohexanol (0.130 mL, 1.22 mmol). The reaction mixture was heated at 62 ºC for 
2.5 h, cooled to room temperature, diluted with ethyl acetate (15 mL), washed with 1 N HCl (2 × 
9 mL), a sat. NaHCO3 solution (1 × 10 mL), and brine (1 × 10 mL), dried (MgSO4), evaporated, 
and purified by chromatography on SiO2 (75% EtOAc/hexanes) to give 2-14 (112 mg, 0.260 
mmol, 86%) as a colorless solid: 1H-NMR (400 MHz, CDCl3) δ 5.53 (d, J = 8.4 Hz, 1 H), 5.40 
(app. t, J = 8.9 Hz, 1 H), 5.04 (t, J = 9.6 Hz, 1 H), 4.86 (d, J = 8.4 Hz, 1 H), 4.26 (dd, J = 4.8 , 
12.0 Hz, 1 H), 4.10 (dd, J = 2.4, 12.0 Hz, 1 H), 3.72-3.58 (m, 3 H), 2.07 (s, 3 H), 2.02 (s, 3 H), 
2.01 (s, 3 H), 1.93 (s, 3 H), 1.92-1.18 (m, 10 H); 13C-NMR (100 MHz, CDCl3) δ 170.8, 170.7, 
170.1, 169.5, 98.9, 77.7, 72.2, 71.6, 69.0, 62.3, 55.6, 33.3, 31.7, 25.5, 23.8, 23.7, 23.4, 20.8, 20.7 
(2 C); HRMS (ESI) m/z calcd for C20H31NO9Na (M+Na) 452.1897, found 452.1898. 
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Geranoyl 3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy-β-D-glucopyranoside (2-15). A solution 
of 2-12 (0.120 g, 0.364 mmol) and anhydrous CuCl2 (49.0 mg, 0.364 mmol) in anhydrous CHCl3 
(0.84 mL) in a 2-5 mL conical sealed vessel under argon atmosphere was treated with geraniol 
(0.270 mL, 1.47 mmol). The reaction mixture was heated at 62 ºC for 2 h, cooled to room 
temperature, diluted with ethyl acetate (15 mL), washed with 1 N HCl (2 × 9 mL), a sat. 
NaHCO3 solution (1 × 10 mL), and brine (1 × 10 mL), dried (MgSO4), evaporated, and purified 
by chromatography on SiO2 (75% EtOAc/hexanes) to give 2-15 (120 mg, 0.248 mmol, 68%) as a 
colorless solid: [α]D – 20.9 (с 1.0, CH2Cl2); Mp 104.8-105.8 ºC; IR (ATR) 3282, 2930, 1743, 
1735, 1650, 1569, 1431, 1368, 1223, 1128, 1077, 1029, 975 cm-1; 1H-NMR (400 MHz, CDCl3) δ 
5.40 (d, J = 8.4 Hz, 1 H), 5.30-5.26 (m, 2 H), 5.08-4.98 (m, 2 H), 4.70 (d, J = 8.4 Hz, 1 H), 4.32-
4.12 (m, 4 H), 3.82 (app. q, J = 8.4 Hz, 1 H), 3.69-3.63 (m, 1 H), 2.11-2.02 (m, 4 H), 2.07 (s, 3 
H), 2.02 (s, 3 H), 2.02 (s, 3 H), 1.94 (s, 3 H), 1.69 (s, 3 H), 1.66 (s, 3 H), 1.60 (s, 3 H); 13C-NMR 
(125 MHz, CDCl3) δ 170.9, 170.7, 170.1, 169.4, 142.2, 131.8, 123.8, 119.2, 98.8, 72.5, 71.9, 
68.7, 65.1, 62.3, 54.9, 39.6, 26.3, 25.7, 23.4, 20.7 (2 C), 20.6, 17.7, 16.3; HRMS (ESI) m/z calcd 
for C24H37NO9Na (M+Na) 506.2366, found 506.2360. 
O
AcO OAc
NHAc
AcO OAc
2-5  
2-Acetamido-2-deoxy-1,3,4,6-tetra-O-acetyl-β-D-galactopyranose (2-5).83,96 A solution of D-
(+)-galactosamine hydrochloride (0.500 g, 2.32 mmol) in anhydrous pyridine (5 mL) was treated 
with acetic anhydride (2.36 mL, 27.8 mmol), stirred at room temperature for 2 d and poured onto 
 68 
ice-cold water (75 mL).  After a white solid precipitated, the solid was collected by vacuum 
filtration, washed with ice-cold water and co-evaporated with toluene (3 × 3 mL) to give 2-5 as a 
colorless powder (745 mg, 1.91 mmol, 83%): 1H-NMR (400 MHz, CDCl3) δ 5.71 (d, J = 8.8 Hz, 
1 H), 5.41-5.37 (m, 2 H), 5.08 (dd, J = 3.2, 11.2 Hz, 1 H), 4.44 (app. q, J = 8.0 Hz, 1 H), 4.20-
4.09 (m, 2 H), 4.02 (app t, J = 6.4 Hz, 1 H), 2.17 (s, 3 H), 2.13 (s, 3 H), 2.05 (s, 3 H), 2.02 (s, 3 
H), 1.94 (s, 3 H). 
O
AcO
N O
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2,3-Dihydrooxazole-3,4,6-tri-O-acetyl-α-D-galactopyranoside (2-6).97 A solution of 2-5 (400 
mg, 1.03 mmol) in dichloroethane (28.6 mL) was treated with TMSOTf (0.200 mL, 1.08 mmol) 
at room temperature, heated at 50 ºC for 1 h, cooled, and treated with NEt3 (0.440 mL, 3.08 
mmol). The mixture was stirred at room temperature for 10 min, passed through a short plug of 
silica and washed with ethyl acetate (25 mL) and dichloromethane (30 mL). The solvent was 
evaporated under reduced pressure and the crude oil was purified by chromatography on SiO2 
(100% EtOAc, base washed with 1% NEt3 prior to use) to yield 2-6 as a clear slight orange oil 
(304 mg, 0.923 mmol, 90%): 1H-NMR (400 MHz, CDCl3) δ 5.98 (d, J = 6.8 Hz, 1 H), 5.45 (d, J 
= 2.8 Hz, 1 H), 4.90 (dd, J = 3.2, 7.2 Hz, 1 H), 4.26-4.16 (m, 2 H), 4.10 (dd, J = 5.6, 11.2 Hz, 1 
H), 3.98 (td, J = 1.2, 7.6 Hz, 1 H), 2.11 (s, 3 H), 2.06 (s, 6 H), 2.04 (d, J = 1.2 Hz, 3 H); 13C-
NMR (100 MHz, CDCl3) δ 170.5, 170.2, 169.8, 166.4, 101.5, 71.8, 69.5, 65.3, 63.6, 61.6, 20.8, 
20.7, 20.6, 14.4; HRMS (ESI) m/z calcd for C14H20NO8 (M+H) 330.1189, found 330.1187. 
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Isopropyl 3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy-β-D-galactopyranoside (2-7). A 
solution of 2-6 (0.133 g, 0.404 mmol) and anhydrous CuCl2 in anhydrous CHCl3 (0.76 mL) in a 
2-5 mL conical sealed vessel under argon atmosphere was treated with anhydrous 2-propanol 
(0.130 mL, 1.72 mmol).  The reaction mixture was heated at 62 ºC for 2 h, cooled to room 
temperature, diluted with acetone (15 mL) and sat. NaHCO3 solution (7 mL) filtered through a 
short plug of Celite®, and concentrated.  The residue was coevaporated with toluene to remove 
residual water and shaken in CHCl3 and weakly acidic ion-exchange resin (Amberlite IRC-86, ca 
1.5 g). The solution was filtered, the solvent was reduced under vacuum, and the residue was 
chromatographed on SiO2 (75% EtOAc/hexanes) to give 2-7 (119 mg, 0.305 mmol, 75%) as a 
colorless solid: [α]D – 14.4 (с 1.0, CH2Cl2); Mp 188.5-189.5 ºC; IR (ATR) 3264, 2980, 1735, 
1648, 1568, 1380, 1256, 1232, 1215, 1124, 1072, 1053, 1023 cm-1; 1H-NMR (600 MHz, CDCl3) 
δ 5.57 (d, J = 7.8 Hz, 1 H), 5.42 (dd, J = 3.0, 11.1 Hz, 1 H), 5.35 (app. d, J = 3.6 Hz, 1 H), 4.86 
(d, J = 8.4 Hz, 1 H), 4.16 (dd, J = 6.6, 11.4 Hz, 1 H), 4.10 (dd, J = 7.2, 11.4 Hz, 1 H), 3.95-3.90 
(m, 2 H), 3.77-3.73 (m, 1 H), 2.12 (s, 3 H), 2.03 (s, 3 H), 1.99 (s, 3 H), 1.94 (s, 3 H), 1.23 (d, J = 
6.6 Hz, 3 H), 1.13 (d, J = 6.6 Hz, 3 H); 13C-NMR (150 MHz, CDCl3) δ 170.5, 170.3, 99.4, 72.8, 
70.4, 69.6, 66.8, 61.5, 52.4, 23.5, 23.3, 22.0, 20.7 (2 C); HRMS (ESI) m/z calcd for C17H28NO9 
(M+H) 390.1764, found 390.1774. 
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Cyclohexyl 3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy-β-D-galactopyranoside (2-8). A 
solution of 2-6 (0.135 g, 0.411 mmol) and anhydrous CuCl2 (55.0 mg, 0.411 mmol) in anhydrous 
CHCl3 (0.68 mL) in a 2-5 mL conical sealed vessel under argon atmosphere was treated with 
cyclohexanol (0.170 mL, 1.66 mmol). The reaction mixture was heated at 62 ºC for 2 h, cooled 
to room temperature, diluted with ethyl acetate (15 mL), washed with 1 N HCl (2 × 9 mL), sat. 
NaHCO3 solution (1 × 10 mL), and brine (1 × 10 mL), dried (MgSO4), evaporated, and purified 
by chromatography on SiO2 (75% EtOAc/hexanes) to give 2-8 (141 mg, 0.328 mmol, 80%) as a 
colorless solid: [α]D – 14.6 (с 1.0, CH2Cl2); Mp 164.3-165.3 ºC; IR (ATR) 3331, 2936, 2857, 
1735, 1661, 1541, 1364, 1251, 1219, 1079, 1031, 984 cm-1; 1H-NMR (500 MHz, CDCl3) δ 5.48 
(d, J = 8.5 Hz, 1 H), 5.41 (dd, J = 3.5, 11.5 Hz, 1 H), 5.35 (app. d, J = 3.5 Hz, 1 H), 4.89 (d, J = 
8.5 Hz, 1 H), 4.17 (dd, J = 6.5, 11.5 Hz, 1 H), 4.10 (dd, J = 7.0, 11.0 Hz, 1 H), 3.91 (app t, J = 
10.5 Hz, 1 H), 3.80-3.74 (m, 1 H), 3.64-3.59 (m, 1 H), 2.13 (s, 3 H), 2.03 (s, 3 H), 1.99 (s, 3 H), 
1.94 (s, 3 H), 1.93-1.17 (m, 10 H); 13C-NMR (125 MHz, CDCl3) δ 170.4, 170.3 (3 C), 99.1, 78.0, 
70.4, 69.6, 66.8, 61.4, 52.5, 33.3, 31.7, 25.5, 23.9, 23.8, 23.5, 20.7 (2 C); HRMS (ESI) m/z calcd 
for C20H32NO9 (M+H) 430.2077, found 430.2084. 
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Geranoyl 3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy-β-D-galactopyranoside (2-9). A 
solution of 2-6 (0.120 g, 0.364 mmol) and anhydrous CuCl2 (49.0 mg, 0.364 mmol) in anhydrous 
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CHCl3 (0.84 mL) in a 2-5 mL conical sealed vessel under argon atmosphere was treated with 
geraniol (0.270 mL, 1.47 mmol). The reaction mixture was heated at 62 ºC for 2 h, cooled to 
room temperature, diluted with ethyl acetate (15 mL), washed with 1 N HCl (2 × 9 mL), sat. 
NaHCO3 solution (1 × 10 mL), and brine (1 × 10 mL), dried (MgSO4), evaporated, and purified 
by chromatography on SiO2 (75% EtOAc/hexanes) to give 2-9 (149 mg, 0.308 mmol, 65%) as a 
colorless solid: [α]D – 17.0 (с 1.0, CH2Cl2); Mp 117.5-118.9 ºC; IR (ATR) 3279, 2982, 2939, 
1737, 1659, 1555, 1536, 1431, 1374, 1241, 1226, 1131, 1064, 1053, 1036, 1012, 997, 958 cm-1; 
1H-NMR (500 MHz, CDCl3) δ 5.41 (d, J = 8.5 Hz, 1 H), 5.36-5.27 (m, 3 H), 5.09-5.06 (m, 1 H), 
4.75 (d, J = 8.5 Hz, 1 H), 4.29 (dd, J = 6.5, 12.0 Hz, 1 H), 4.23-4.11 (m, 3 H), 4.94-3.88 (m, 2 
H), 2.13 (s, 3 H), 2.12-2.00 (m, 4 H), 2.03 (s, 3 H), 1.99 (s, 3 H), 1.94 (s, 3 H), 1.68 (s, 3 H), 1.65 
(s, 3 H), 1.60 (s, 3 H), ; 13C-NMR (125 MHz, CDCl3) δ 170.4 (2 C), 170.3, 170.2, 142.1, 131.8, 
123.8, 119.3, 99.0, 70.6, 69.9, 66.9, 65.2, 61.6, 51.8, 39.6, 26.3, 25.7, 23.5, 20.7 (2 C), 17.7, 
16.3; HRMS (ESI) m/z calcd for C24H37NO9Na (M+Na) 506.2366, found 506.2384. 
O
AcO
AcHN
AcO
OAc
2-16 O
 
Isopropyl 3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy-α-D-glucopyranoside (2-16).98 A 
solution of 2-11 (50.0 mg, 0.128 mmol) in a 5% HCl solution in 2-propanol (3.8 mL) was stirred 
at 65 ºC for 1 h, evaporated to dryness, dissolved in pyridine (0.48 mL) and treated with acetic 
anhydride (0.146 mL, 1.54 mmol). The reaction mixture was stirred at room temperature for 2 d 
and then coevaporated with toluene to give a brown oil which was a 3:1 mixture of α:β-isomers 
by crude NMR. Purification by chromatography  on SiO2 (75% EtOAc/hexanes) gave 2-16 (30.4 
mg, 0.0781 mmol, 61%) as a foaming colorless solid: IR (ATR) 3359, 2975, 1750, 1730, 1676, 
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1534, 1437, 1376, 1364, 1243, 1225, 1150, 1122, 1038, 1031, 997 cm-1; 1H-NMR (400 MHz, 
CDCl3) δ 5.62 (d, J = 9.6 Hz, 1 H), 5.19 (app t, J = 9.6 Hz, 1 H), 5.10 (app t, J = 9.6 Hz, 1 H), 
4.92 (d, J = 3.8 Hz, 1 H), 4.30 (td, J = 3.6, 9.6 Hz, 1 H), 4.22 (dd, J = 4.8, 12.4 Hz, 1 H), 4.08 
(dd, J = 2.4, 12.4 Hz, 1 H), 4.03-3.99 (m, 1 H), 3.88 (sept, J = 6.0 Hz, 1 H), 2.07 (s, 3 H), 2.02 (s, 
3 H), 2.01 (s, 3 H), 1.93 (s, 3 H), 1.23 (d, J = 6.4 Hz, 3 H), 1.14 (d, J = 6.4 Hz, 3 H); 13C-NMR 
(100 MHz, CDCl3) δ 171.4, 170.7, 169.8, 169.3, 95.7, 71.4, 71.0, 68.2, 67.7, 62.0, 51.8, 23.2, 
23.1, 21.6, 20.7 (2 C), 20.6; HRMS (ESI) m/z calcd for C17H28NO9 (M+H) 390.1764, found 
390.1790. 
O
AcO
AcHN
OAc
2-17
AcO
O
 
Isopropyl 3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy-α-D-galactopyranoside (2-17).98 A 
solution of 2-5 (50.0 mg, 0.128 mmol) in a 5% HCl solution in 2-propanol (3.8 mL) was stirred 
at 65 ºC for 1 h, evaporated to dryness, dissolved in pyridine (0.50 mL) and treated with acetic 
anhydride (0.146 mL, 1.54 mmol). The reaction mixture was stirred at room temperature for 2 d 
and then coevaporated with toluene to give a brown oil that was a 3:1 mixture of α:β-isomers by 
crude NMR.  Purification by chromatography on SiO2 (75% EtOAc/hexanes) gave 2-17 (28.6 
mg, 0.0737 mmol, 57%) as a foaming colorless solid: IR (ATR) 3310, 2973, 2930, 1745, 1732, 
1653, 1534, 1372, 1284, 1240, 1217, 1124, 1083, 1034, 992, 936, 878 cm-1; 1H-NMR (400 MHz, 
CDCl3) δ 5.54 (d, J = 9.6 Hz, 1 H), 5.35 (app. d, J = 2.8 Hz, 1 H), 5.13 (dd, J = 3.2, 11.2 Hz, 1 
H), 4.95 (d, J = 4.0 Hz, 1 H), 4.56-4.50 (m, 1 H), 4.23 (app. t, J = 6.8 Hz, 1 H), 4.12-4.02 (m, 2 
H), 3.88 (sept, J = 6.0 Hz, 1 H), 2.15 (s, 3 H), 2.03 (s, 3 H), 1.98 (s, 3 H), 1.95 (s, 3 H), 1.22 (d, J 
= 6.0 Hz, 3 H), 1.13 (d, J = 6.4 Hz, 3 H); 13C-NMR (100 MHz, CDCl3) δ 171.0, 170.4 (2 C), 
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169.9, 96.3, 71.0, 68.5, 67.5, 66.7, 62.0, 47.8, 23.3, 23.1, 21.7, 20.8, 20.7, 20.6; HRMS (ESI) m/z 
calcd for C17H28NO9 (M+H) 390.1764, found 390.1776. 
O
AcO
AcHN
AcO
OAc
2-18 O
 
Cyclohexyl 3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy-α-D-glucopyranoside (2-18).99 A 
solution of 2-11 (50.0 mg, 0.128 mmol) in a 5% HCl solution in cyclohexanol (3.1 mL) was 
stirred at 65 ºC for 1 h, evaporated to dryness, dissolved in pyridine (0.50 mL, anhydrous) and 
treated with acetic anhydride (0.146 mL, 1.54 mmol). The reaction mixture was stirred at room 
temperature for 31 h and coevaporated with toluene to give a brown oil that was a 3:1 mixture of 
α:β-isomers by crude NMR. Purification by chromatography on SiO2 (75% EtOAc/hexanes) 
gave 2-18 (31.7 mg, 0.0738 mmol, 57%) as a foaming colorless solid: 1H-NMR (400 MHz, 
CDCl3) δ 5.63 (d, J = 9.6 Hz, 1 H), 5.19 (app. t, J = 10.2 Hz, 1 H), 5.08 (app. t, J = 10.8 Hz, 1 
H), 4.96 (d, J = 3.6 Hz, 1 H), 4.32-4.26 (m, 1 H), 4.21 (dd, J = 4.8, 12.4 Hz, 1 H), 4.08 (dd, J = 
2.4, 12.4 Hz, 1 H), 3.54 (sept, J = 4.0 Hz, 1 H), 2.07 (s, 3 H), 2.01 (s, 3 H), 2.00 (s, 3 H), 1.93 (s, 
3 H), 1.91-1.20 (m, 10 H); 13C-NMR (100 MHz, CDCl3) δ 171.4, 170.7, 169.8, 169.3, 95.6, 71.4, 
68.2, 67.7, 62.0, 51.9, 33.3, 31.5, 25.4, 24.1, 23.8, 23.2, 20.7 (2 C), 20.6; HRMS (ESI) m/z calcd 
for C20H32NO9 (M+H) 430.2077, found 430.2086. 
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2-19
 
Cyclohexenyl 3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy-β-D-glucopyranoside (2-19). A 
solution of 2-12 (0.128 g, 0.388 mmol) and anhydrous CuCl2 (52.0 mg, 0.388 mmol) in 
anhydrous CHCl3 (0.88 mL) in a 2-5 mL conical sealed vessel under argon atmosphere was 
treated with cyclohexenol (0.16 mL, 1.57 mmol). The reaction mixture was heated at 62 ºC for 2 
h, cooled to room temperature, diluted with ethyl acetate (25 mL), washed with 1 N HCl (2 × 9 
mL), sat. NaHCO3 solution (1 × 10 mL), and brine (1 × 10 mL), dried (MgSO4), evaporated, and 
purified by chromatography on SiO2 (75% EtOAc/hexanes) to give 2-19 (61.7 mg, 0.144 mmol, 
37%, 1:1 mixture of diastereomers) as a colorless solid: [α]D – 16.7 (с 1.0, CH2Cl2); Mp 177.8-
178.9 ºC; IR (ATR) 3271, 3096, 2941, 1745, 1737, 1650, 1558, 1431, 1368, 1221, 1159, 1038, 
733 cm-1; 1H-NMR (400 MHz, CDCl3) δ 5.90-5.84 (m, 2 H), 5.78-5.71 (m,  1H), 5.71-5.65 (m, 1 
H), 5.58-5.45 (m, 3 H), 5.42-5.35 (m, 1 H), 5.07-5.00 (m, 2 H), 4.98 (d, J = 8.4 Hz, 1 H), 4.91 (d, 
J = 8.0 Hz, 1 H), 4.30-4.15 (m, 4 H), 4.12 (dd, J = 2.4, 12.0 Hz, 2 H), 3.75-3.65 (m, 3 H), 3.61-
3.54 (m, 1 H), 2.08 (s, 6 H), 2.02 (2 x s, 12 H), 1.93 (2 x s, 6 H), 1.86-1.50 (m, 8 H); 13C-NMR 
(100 MHz, CDCl3) δ 170.8, 170.6, 170.2 (2 C), 169.5, 169.5, 132.3, 131.7, 127.5, 126.3, 99.1, 
98.7, 73.1, 72.8, 71.9, 71.6, 69.0, 68.9, 62.3, 55.9, 55.5, 29.7, 28.3, 25.1, 25.0, 23.4, 20.8, 20.7 (2 
C), 18.9, 18.6; HRMS (ESI) m/z calcd for C20H29NO9Na (M+Na) 450.1740, found 450.1745. 
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2-14
 
Cyclohexyl 3,4,6-tri-O-acetyl-2-(acetylamino)-2-deoxy-β-D-glucopyranoside.95 A solution of 
2-19 (20.0 mg, 0.047 mmol) in ethyl acetate (1.7 mL) was treated with 10% Pd/C (3.2 mg, 
0.0030 mmol). The flask was evacuated, purged with H2, stirred for 2 h under an atmosphere of 
H2, filtered through Celite® and evaporated to give 2-14 as colorless powder (19.7 mg, 0.0454 
mmol, 97%): 1H-NMR (400 MHz, CDCl3) δ 5.57 (d, J = 8.4 Hz, 1 H), 5.40 (app. t, J = 9.2 Hz, 1 
H), 5.04 (t, J = 9.6 Hz, 1 H), 4.86 (d, J = 8.4 Hz, 1 H), 4.26 (dd, J = 4.8 , 12.0 Hz, 1 H), 4.10 (dd, 
J = 2.4, 12.0 Hz, 1 H), 3.72-3.58 (m, 3 H), 2.07 (s, 3 H), 2.02 (s, 3 H), 2.01 (s, 3 H), 1.93 (s, 3 
H), 1.91-1.18 (m, 10 H); 13C-NMR (100 MHz, CDCl3) δ 170.8, 170.2, 169.5, 98.9, 77.7, 72.1, 
71.5, 68.9, 62.3, 55.5, 33.2, 31.6, 25.5, 23.8, 23.7, 23.4, 20.8, 20.7 (2 C). 
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